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CROSS REACTIVE ARRAYS OF THREE-WAY 
JUNCTION SENSORS FOR STEROID 
DETERMINATION 
pocket. The shapes and sizes of junctions could be varied 
through changes in primary structure, and junctions can eas- 
ily be turned into fluorescent sensors. These receptors are 
conceptually similar to various cyclodextrins, cyclophanes, 
calixarenes and other synthetic lipophylic cavities, which 
were earlier used to construct fluorescent sensors. Differ- 
ences between nucleic acid-based sensors and other struc- 
n i S  application is a continuation-in-part  of^,^, ser, N ~ ,  
10/824,158, filed 14, 2004 now abandoned, which 
claims the benefit of U,S, provisiona~ ~ ~ ~ l i ~ ~ ~ i ~ ~  N ~ ,  
601462,206, filed Apr. 14, 2003; and a continuation of PCT 
International Application No. pCT/US2004/011696, filed 
tures 
haps most 
the straightfornard synthetic approach and, per- 
construction Of a large 
Apr. 15,2004, the contents of all of which are hereby incor- 
porated by reference. 
of the subject matter disclosed herein was 
supported by grants from NASA (NAs2-02039) and NIH 
may have rights to subject matter disclosed herein. 
BACKGROUND OF THE INVENTION 
number Of 
The significance of the subject matter of the present inven- 
tion is multifold. First, one canexpand the scope ofmolecules 
and matrices where arrays could be applied to biologically 
results and construct arrays that could report steroids inurine. 
15 Second, one can come closer to mimicking the resolution 
power of mammalian olfactory sense by incorporating in 
these arrays large number of closely related, yet distinct, 
sensors. This will become especially significant when one 
Throughout this application, various publications are ref- large arrays to characterize urine, which contains numer- 
erenced to as footnotes or within Parentheses. Dischures of 2o ous structurally related molecules that are traditionally chal- 
these publications in their entireties are hereby incorporated lenging to analyze, Third, from the practical point ofview, the 
by reference into this application to more fully describe the ability to rapidly determine hy&ophobic content ofurine will 
state of the art to which this invention pertains. Full biblio- lead to immediate routine applications in general health 
graphic citations for these references may be found within or monitoring and diagnosis, ~ ~ ~ ~ l ~ ,  any gross deviation from 
at the end of this application, preceding the claims. the normal pattern of steroid excretion will be immediately 
The mammalian olfactory system consists of approxi- 25 detectable and will be correlated to the clinical conditions 
matelY one thOusand unique receptors (1). The distinctive (e.g. endocrinopathy of steroid-based hormones or positive 
characteristic ofthis system is cross-reactivity, i.e. one recep- toxicoloa screens), Fourth, the successful development of 
tor may react with many odorants, and one odorant may react the first nucleic acid-based cross-reacting arrays for hydro- 
with many receptors. Thus, an odorant is not characterized by phobic fingerprinting will provide an impetus for other cross- 
a single and specific interaction, but rather through a pattern 30 reactive nucleic acid-based arrays, for which no comparable 
of massively Parallel responses Yielding fingerprints charac- methods exist (e.g., for monitoring of blood and urinary oli- 
teristic for that specific odorant. Attempts to mimic the mam- gosacharides and glycoprotein glycoforms), which will result 
malian olfactory system have led to the development of “elec- in the construction of advanced arrayed labs-on-chips, Fifth, 
trOniC noses”, or arrays Of Cross-reactive sensors (2). In cross- the screening ofa  large number ofhydrophobic receptors for 
analytical samples are matched through their characteristic yield Some members that will be highly specific in the context 
fingerprints to available standards. However, the frameworks of certain applications (for example ultra-high throughput 
suitable for the incremental variations of structure necessary screening applications, 
to achieve differential cross-reactivity are currently limited. It The present invention provides a composition comprising 
would be useful to Provide b~Omolecular eceptors based on an oligonucleotide which comprises consecutive nucleotides 
nucleic-acid three-way junctions that can be adapted to yield 40 having the sequences set forth in SEQ ID  NO:^ and SEQ ID 
cross-reacting arrays for fingerprinting of solutions contain- ~ 0 ~ 2 ,  wherein SEQ ID  NO:^ is located 51 to SEQ ID ~ 0 ~ 2 ,  
ing hydrophobic molecules. The present invention further provides the instant oligo- 
nucleotide, wherein the oligonucleotide folds so that the 
._  sequences set forth in SEQ ID NO:1 and SEQ ID NO:1 
different structures. 
At least 
(NlBlB, R01 EB000675-1). The United States Government analytes. One can first expand On 
reactive arrays, instead of &~ndard dose-response curves, 35 transduction of recognition into optical readout will likely 
SUMMARY OF THE INVENTION 
contained in the oligonucleotide are arranged as set forth in 
the following structure, wherein SEQ ID NO: 1 is the left hand 
sequence and SEQ ID NO:2 is the right hand sequence: 
43 
The Present invention recognizes and Provides using bio- 
molecules productively in cross-reacting arrays. The present 
invention provides an array based on nucleic-acids capable of 
fingerprinting hydrophobic molecules in solutions. With the 
recognition of a class of DNA-based molecular sensors for 50 5’ 
hydrophobic molecules as a starting point, the present inven- \G----c/3’ 
I 1  
C.---G 
tion provides for construction of an array from a large number 
instantaneously hydrophobic surfaces in urine belonging to 
steroids, alkaloids or any other hydrophobic drugs and corre- 55 
late these fingerprints with disease states. This approach can 
be expanded to other biologically relevant molecules. Con- 
struction of large arrays on microchips that will incorporate 
different types of cross-reactive molecular sensors will lead 
to the rapid, one step procedures for diagnostic purposes. 
nucleic acid junctions has been noticed during early foot- 
printing studies on these structures. These observations have 
of unique sensors. Such an array will be able to fingerprint A----T 
A 
‘A 
‘G-G-T-G/ 
,c-A-.~-T, / 
I I  
I j  
,A%. / 
/G..* /T 
** T G 
Incorporation of hydrophobic molecules into various 6o 
’C 
\ 
been confirmed by the isolation of anti-steroid aptamers that 
were based on fully matched junctions. Also, one can isolate 
and characterize the first cocaine-binding junctions with mis- 65 
matched stems. Unstacked base pairs at the ends of double 
helixes that form these junctions define the hydrophobic 
The present invention further provides the instant oligo- 
nucleotide, wherein the oligonucleotide comprises consecu- 
tive nucleotides having the sequence set forth in SEQ ID 
US 7,4703 16 B2 
3 4 
NO: 152, wherein SEQ ID NO: 152 is located 3' to SEQ ID 
NO: 1 and 5' to SEQ ID NO:2. 
The present invention also provides composition compris- 
ing an oligonucleotide which comprises consecutive nucle- 
otides having the sequences set forth in SEQ ID NO: 101 and 5 
SEQ ID NO: 102, wherein SEQ ID NO: 101 is located 5' to 
SEQ ID NO:102. 
The present invention further provides the instant oligo- 
nucleotide, wherein the oligonucleotide folds so that the 
sequences set forth in SEQ ID NO: 101 and SEQ ID NO: 102 10 
contained in the oligonucleotide are arranged as set forth in 
the following structure, wherein SEQ ID NO: 1-1 is the left 
hand sequence and SEQ ID NO:102 is the right hand 
sequence: 
(b) contacting the composition with the first solution con- 
(c) quantitating the fluorescence of the fluorescent moiety 
(d) washing the composition to remove the first solution; 
(e) contacting the composition with the second solution 
containing the analyte; 
(f) quantitating the fluorescence ofthe fluorescent moiety 
of the composition; and 
(g) comparing the fluorescence quantitated in step (f) With 
that quantitated in step (c), 
wherein a change in the fluorescence quantitatedin step (f) 
as compared with the fluorescence quantitated in step (c) 
indicates that the amount of the analyte in the first solu- 
tion is different to the amount of the analyte in the 
second solution. 
This invention also provides a method of quantitating an 
(a) providing a composition comprising anoligonucleotide 
and a fluorescent moiety attached to the oligonucleotide, 
wherein the oligonucleotide undergoes a conforma- 1 ,-G tional change upon contact with the analyte and the 
1 : :  'A fluorescent moiety undergoes a change of fluorescence 
upon the conformational change; 
'T 25 (b) providing a predetermined relationship between the 
fluorescent moiety fluorescence and the analyte concen- 
(c) contacting the composition with the solution containing 
the analyte; 
(d) quantitating the fluorescence of the fluorescent moiety 
of the composition in contact with the solution contain- 
The present invention further provides the instant compo- ing the analyte; 
sitions, wherein the oligonucleotide comprises consecutive (e) quantitating the analyte in the solution from the fluo- 
nucleotides having the sequence set forth in SEQ ID NO: 153, rescence quantitated in step (d) and the predetermined 
wherein SEQ ID NO: 153 is located 3'to SEQ ID NO: 101 and 35 
5' to SEQ ID NO:102. This invention also provides the instant methods, wherein 
This invention also provides a method of detecting an two or 
analyte in a solution comprising: This invention also provides a method of determining 
(a) providing a composition comprising an oligonucleotide whether a first solution comprising a first analyte has an 
and a fluorescent moiety attached to the oligonucleotide, 40 analyte composition different to that of a second solution 
wherein the oligonucleotide undergoes a conforma- comprising a second analyte comprising: 
tional change upon contact with the analyte and the (a) providing a first composition comprising a first oligo- 
fluorescent moiety undergoes a change of fluorescence nucleotide and a first fluorescent moiety attached to the 
upon the conformational change; first oligonucleotide, and a second composition com- 
(b) quantitating the fluorescence of the fluorescent moiety 45 prising a second oligonucleotide and a second fluores- 
of the composition in the absence of the analyte; cent moiety attached to the second oligonucleotide, 
(c) subsequently contacting the composition with the solu- wherein each of the first and second oligonucleotides 
tion containing the analyte; undergoes a conformational change upon contact with 
the first analyte and upon contact with the second ana- (d) quantitating the fluorescence of the fluorescent moiety 
change of fluorescence upon the conformational change 
of the oligonucleotides upon contact with the first ana- 
lyte and upon contact with the second analyte; 
(b) contacting the first composition and second composi- 
(c) quantitating the fluorescence of each of the fluorescent 
(d) washing to remove the first solution; 
(e) contacting the first composition and second composi- 
tion with the second solution containing the second ana- 
taining the analyte; 
of the composition; 
15 
analyte in a solution comprising: 3' 2' 
20 
'G- I - -7 
A--*-T 
C* 'G-G-T-GRA 
,A%. ,c-A-~-T, G 1 
/A*. / 
'T 
/G.. / tration; 
30 
*c\ 
provided in step (b), 
compositions are present, 
ofthe composition in contact with the solution contain- 50 bte, and each Of the fluorescent moieties undergoes a 
ing the analyte; and 
that quantitated in step (d), 
as comparedwith the fluorescence quantitated in step (b) 
indicates that the analyte is present in the solution. 
This invention also provides a method of determining 
whether an amount of an analyte in a first solution is different 
to that of an amount of the analyte in a second solution 60 
comprising: lyte; 
(e) comparing the fluorescence quantitated in step (b) with 
wherein a change in the fluorescence quantitated in step (dl 55 tion with the first solution containing the first analyte; 
moieties; 
(a) providing a composition comprising an oligonucleotide 
and a fluorescent moiety attached to the oligonucleotide, 
wherein the oligonucleotide undergoes a conforma- 
tional change upon contact with the analyte and the 65 
fluorescent moiety undergoes a change of fluorescence 
upon the conformational change; 
(f) quantitating the fluorescence of each of the fluorescent 
moieties; and 
(g) comparing the fluorescence quantitated in step (f) with 
that quantitated in step (c), 
wherein a change in the fluorescence quantitated in step (f) 
as compared with the fluorescence quantitated in step (c) 
US 7,4703 16 B2 
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indicates that the first solution containing the first ana- 
lyte has an analyte composition different to that of the 
second solution containing the second analyte. 
FIG. 7: Oligonucleotide structures 61 -70 comprising con- 
secutive nucleotides. Broken lines between bases represent 
hydrogen bonding. Structures run from 3' top left to 5' top 
right, and comprise a hydrophobic pocket by which the ana- 
5 lyte (S) can be contained. SEQ ID NOS. for sequences are 
denoted by SEQ. X, whereinX is integer. The g ofthe g-c pair 
FIG, 1: O~igonuc~eotide structures 1-10 comprising con- bottom is joined by consecutive nucleotides to the c of the g-c 
secutive nucleotides. Broken lines between bases represent Pair bottom left (not shown) e.!& by SEQ ID NO:153. F is a 
hydrogen bonding. Structures run from 5' top left to 3' top fluorophore, and also represents the Position of a Phospho- 
right, and comprise a hydrophobic pocket by which the ana- 10 rothioak bond. 
lyte (s) can be contained, SEQ ID  NO^, for sequences are FIG. 8: Oligonucleotide structures 71-80 comprising con- 
denotedby SEQ, x, whereinX is integer, The ofthe g-c pair secutive nucleotides. Broken lines between bases represent 
bottom is joined by consecutive nucleotides to the c of the g-c hydrogen bonding. Structures run from 3' top left to 5' top 
pair bottom left (not shown) e.g. by SEQ ID NO: 152. F is a right, and comprise a hydrophobic Pocket by which the ana- 
fluorophore, and also represents the position of a phospho- 15 1Yte (s) can be contained. SEQ ID Nos. for sequences are 
rothioate bond. denoted by SEQ. X, whereinX is integer. The g ofthe g-c pair 
-20 comprising con- bottom is joined by consecutive nucleotides to the c of the g-c 
secutive nucleotides. Broken lines between bases represent pair bottom left (not shown) is a 
right, and comprise a hydrophobic pocket by which the ana- 2o rothioate bond. 
lyte can be contained, SEQ ID for sequences are 
denotedby SEQ, x, whereinX is integer, The ofthe g-c pair 
DESCRIPTION OF THE DRAWINGS 
FIG, 2: O~igonuc~eotide structures 
by SEQ ID 
hydrogen bonding, Structures run from 5' top left to 3' top fluorophore, and represents the position Of a phospho- 
FIG. 9: Oligonucleotide structures 81-90 comprising con- 
secutive nucleotides. Broken lines between bases represent 
bottom is joined by consecutive nucleotides to the c ofthe g-c Structures run from 3' top left to 5' top 
pair bottom left (not shown) e,g, by SEQ ID NO:152, F is a right, and comprise a hydrophobic pocket by which the ana- 
fluorophore, and also represents the position of a phospho- 25 1Yte (SI can be contained. SEQ ID NOS. for sequences are 
denoted by SEQ. X, whereinX is integer. The g ofthe g-c pair 
bottom is joined by consecutive nucleotides to the c of the g-c 
pair bottom left (not shown) e.g. by SEQ ID NO:153. F is a 
fluorophore, and also represents the position of a phospho- 
FIG. 10: Oligonucleotide structures 91-100 comprising 
consecutive nucleotides. Broken lines between bases repre- 
sent hydrogen bonding. Structures run from 3'top left to 5'top 
right, and comprise a hydrophobic pocket by which the ana- 
's a 35 lyte (S) can be contained. SEQ ID NOS. for sequences are 
denoted by SEQ. X, whereinX is integer. The g ofthe g-c pair 
bottom is joined by consecutive nucleotides to the c of the g-c 
pair bottom left (not shown) e,g, by SEQ ID NO:153, F is a 
fluorophore, and also represents the position of a phospho- 
rothioate bond. 
FIG. 3: Oligonucleotide structures 21 -30 comprising con- 
secutive nucleotides. Broken lines between bases represent 
hydrogen bonding. Structures run from 5' top left to 3' top 
right, and comprise a hydrophobic pocket by which the ana- 
lyte (S) can be contained. SEQ ID NOS. for sequences are 
denoted by SEQ. X, whereinX is integer. The g ofthe g-c pair 
bottom is joined by consecutive nucleotides to the c of the g-c 
pair bottom left (not shown) e'g' by SEQ ID 
fluorophore, and also represents the position of a phospho- 
rothioate bond. 
FIG. 4: Oligonucleotide structures 31-40 comprising con- 
secutive nucleotides. Broken lines between bases represent 
hydrogen bonding. Structures run from 5' top left to 3' top 4o rothioate bond, 
lyte ('1 can be contained. SEQ ID Nos. for sequences are 
bottom is joined by consecutive nucleotides to the c of the g-c 
30 rothioate bond. 
right, and comprise a hydrophobic pocket by which the ana- FIG, 11: Self-assembling sensor for cocaine andATP oper- 
ating in parallel in solution. Cocaine sensor reports concen- 
sor reports through the quenching ofaodamine x, From left 
denoted SEQ. x, whereinX is integer. The Of the g-' Pair tration through the quenching of fluorescein, while ATP sen- 
is a 45 to right the SEQ ID Nos, for each of the sensors before 
assembly are SEQ ID Nos, 154, 155, 156, and 157, respec- 
pair bottom left (not shown) e.g. by SEQ ID 
fluorophore, and represents the position Of a phospho- 
rothioate bond. tively. 
FIG. 5: Oligonucleotide structures 41 -50 comprising con- FIG. 12: Cocaine sensors fold around cocaine molecule in 
secutive nucleotides. Broken lines between bases represent solution, and signals this conformationa~ change through 
hydrogen bonding. Structures run from 5' top left to 3' top 50 fluorescence quenching of fluorescein. (SEQ ID NO. 158). 
right, and comprise a hydrophobic Pocket by which the ana- FIG. 13: Release of the hydrophobic dye from cocaine 
1Yte (s) Can be contained. SEQ ID Nos. for sequences are aptamer: Dye is precomplexed to aptamers, and it is released 
denotedbY SEQ. x, WhereinX is integer. The g ofthe g-c Pair upon addition of cocaine. This process leads to the attenua- 
bottom is joined by consecutive nucleotides to the c of the g-c tion ofabsorbance, and it could be used to presence of 
pair bottom left (not shown) e.g. by SEQ ID NO:152. F is a 55 cocaine in solution, (SEQ ID NO, 159). 
fluorophore, and also represents the Position of a Phospho- FIG. 14: A schematic representation of the sensors based 
rothioate bond. on three-way junction with a single phosphorothioate, that is 
FIG. 6: Oligonucleotide structures 5 1-60 comprising con- derivatized with fluorophore (F). Black ellipsoid represents 
secutive nucleotides. Broken lines between bases represent hydrophobic molecule that upon binding displaces fluoro- 
hydrogen bonding. Structures run from 3' top left to 5' top 60 phore, causing an increase in fluorescence (larger font). Only 
right, and comprise a hydrophobic pocket by which the ana- one phosphorothioate isomer is shown. 
lyte (S) can be contained. SEQ ID NOS. for sequences are FIG. 15: Molecular sensor based on three-way junction 
denoted by SEQ. X, whereinX is integer. The g ofthe g-c pair signals binding of hydrophobic molecules (black dot). Phos- 
bottom is joined by consecutive nucleotides to the c ofthe g-c phorothioate bond is derivatized with thiol-reactive fluoro- 
pair bottom left (not shown) e.g. by SEQ ID NO:153. F is a 65 phore. (SEQ ID NO. 160). 
fluorophore, and also represents the position of a phospho- FIG. 16: Cross-reactive array from three three-way junc- 
rothioate bond. tions detecting cocaine (C, 1 mM), deoxycholic acid (DC, 2 
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mM) and corticosterone (CS, 120 pM). Bars are responses 
(increase in fluorescence intensity) fromjunction l (dark gray 
bars), from junction 2 (black bars) and light from junction 3 
(squares) and sodium deoxycholate 4 (triangles). All mea- 
surement were taken in triplicates and standard deviation is 
shown. 
(light gray). Experiment was performed in 96-we11 plates. 
SEQ ID Nos. for each three-way junction, in a 
fashion with the leftmost sequence, are SEQ ID Nos. 
161, 162, 163 ("1; 161, 164, 163 (#2) and 165, 166 and 167' 
FIG, 27: Fingerprints based on an array of eight sensors: 
cocaine 1 (500 pM) deoxycorticosterone 21-glucoside 2 (32 
@f), dehy~oisoan~osterone 3-sulfate 3 (125 pM) and 
deoxycho~ic acid 4 (2 mM), (first bar in each group: fmtch- FIG. 17: Representative three-way junctions (9 illustrative 32F33; (second bar): A23-32F33; (third bar): 624-32F33; examples, for brevity only three base pairs in each stem, and 
(fourth bar):T25-32F33; (fifth bar): 4.1-32F33; (six bar): 4.1- no loops are shown) which may be custom made and deriva- i o  
7F8; (7th bar): 4.122F23; (eighth bar): 4.1-31F32. Response tized with fluorophores to yield sensors. The black dots mark 
matched base pairs. SEQ ID NOS. for each three-way junc- ligands, and was used as a reference point to choose concen- 
tion, in a counter-clockwise fashion starting with the leftmost trations. 
sequence, are SEQIDNOs. l68,169,17O(Jl); 171,172,170 15 FIG. 28: The fingerprints (?! Increase in fluorescence vs. 
(J2); 173, 174, 175 (J3); 173, 176, 177 (J4); 178, 179, 1x0 concentration in pM) based on an array of seven sensors of 
(J5); 1x1, 1x2, 183 (J6); 184, 185, 186 (J7); 187, 1x8, 189 cocaine 1, deoxycorticosterone 21-glucoside 2, dehydroi- 
(J9); and 190, 191, 192 (J11). soandrosterone 3-sulfate 3 and deoxycholic acid 4; (first bar 
FIG. 18: Representative modified nucleotides that may be in each group): 4.1-32~33; (second bar): G24-32$33; (third 
incorporated in junctions and tested. Note, methyl phospho- 20 bar): 4.1-7F8; (fourth bar): fmtch-32S33. All measurements 
nate will give electroneutral junction, while 2'-amino deriva- are in triplicates, with 
tive will give junction with additional one positive charge. 
without phosphorothioate. units) of urine (U), urine spiked with deoxycorticosterone 
FIG. 19: An example ofthe synthesis ofmolecular sensors 25 21-g1ucoside (U+2) and urine spiked with dehydroisoandros- 
on solid support. 5'-amine modifiedjunction is attached to the krone 3-dfa te  (u+3) (first bar in each group): 4.1-7F8; 
solid support through reaction with epoxide, followed by (second bar): fmtCh-AZ3-32F33; (third bar) fmtch-T25- 
derivatization of junction with fluorophore. 32F33; (fourth bar): 4.1-32F33. Triplicate measurements of 
FIG. 20: A schematic representation of sensors based on fluorescence intensity were taken, with standard deviation 
neutral junctions. Black ellipsoid represents hydrophobic 30 shown. 
molecule that upon binding displaces fluorophore, causing an FIGS. 30A-30Z, 31A-31Z, and 32A-32N: Plots of indi- 
increase in fluorescence. Only one isomer is shown. vidual sensor fluorescent response to analyte concentration 
region of a nucleic acids-based receptor with a ligand guest 'MNS' is a laboratory code given to during screening, 
(black circle). Further variations in junction structure could 35 Underlinedportion of the sequence structure folds into three- 
A schematic representation of junctions, with guest mol- tions ff is fluorescent analog of T (or U) and R is rhodamine ecules (black square) shows the three aromatic unstacked green analog of T (or U); these are directly constructed sen- surfaces separated by phosphodiester groups forming a sors, without any need to derivatize them. A '*' is a 
phoshorothioate analog (P(S-)(O)(OR),) of phosphodiester FIG. 22: The junctional structures of each sensor, with the bond (P(0-)(O)(OR),)-these precursors were derivatized position of fluorophore attachment indicated (F-fluores- with 6-iodoacetoamido fluorescein in order to construct sen- cein). These five junctions differ in the position of mis- sors. m is a methylphoshonate (P(O)(Me)(OR),) analog of 
32sF33); 194 and 195 (left and right sequences, A23- 45 modifier dT analog, '2NH,- is 2'-amino derivatized 
32sF33); 194 and 196 (left and right sequences' G24- analog.-are spacers, usually 18 atom spacer, but could be 
NI-nitroindol analog. The y-axis is given as a fraction and 194 and 198 (left and right sequences, 4.1-32F33). FIG. 23: The five isomeric sensors, based on the junction increase in fluorescence ((F-Fo)/Fo). x-axis is given in ana- MNS4.1, with varying positions of fluorophore, as shown. 50 lyte concentrations in mM. cor-cortisone, NaDe sodium 
Gz6AA loop in s3 stem not shown' SEQ ID Nos' for each deoxycholate, Coc-cocaine, DIASAehydroisoandroster- 
structure are 104, 199 and 200, starting with the leftmost one 3-sulfate, DOGAeoxycorticosterone 2 1 -glucoside. sequence. 
positions of individual phosphorothioate bonds, lines mis- from 4.1-32F33 (fifth bar) was nearly identical to four 
deviations shown, 
2f-amine can be also directly modified with a fluorophore, 29: Fingerprints (fluorescence intensity, 
FIG. 21: The generic structure of the three-way junction (SEQ ID Nos 154-178; 179-203; and 204-217 respectively, 
be introduced by mismatches and (unpaired bases). B. way junction, with or without mismatches, bulges, modifica- 
hydrophobic binding pocket. 40 
matches (boxed) in the ' 3  stem. SEQ ID Nos. 193 (fmtc- phosphodiester bond, is a propinyl analog, aT is amino- 
32sF33); 194 and 197 (left and right sequences, T25-32F33); shorter, spacers (C9, C3, dSpacer, examples not inclusive), 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
FIG. 24: Schematic representation of the core structures of 
a three-way junction with A. One out of three junctional 55 
phosphodiester groups substituted with a phosphorothioate 
group; B. Fluorescein (F) attached to the reactive sulfur 
through reaction with 6-IAF (one diastereomer shown); C, The present invention provides a composition comprising 
F~uorophore internally displaced from the cavity ofthe three- an oligonucleotide which comprises consecutive nucleotides 
way junction by hydrophobic molecule (black ellipse). 60 having the sequences set forth in SEQ ID NO11 and SEQ ID 
FIG. 25: The structures of four ligands: cocaine (l), deoxy- NO:? wherein SEQ ID NO11 is located 5' to SEQ ID NO:2. 
corticosterone 2 1 -glucoside (2), dehydroisoandrosterone The present invention further provides the instant oligo- 
3-sulfate (3) and deoxycholic acid (4). nucleotide, wherein the oligonucleotide folds so that the 
FIG. 26: Increase in fluorescence intensity (?!) vs. ligand sequences set forth in SEQ ID NO:1 and SEQ ID NO:1 
concentration (pM) for 4.1-32sF33. Ligands: cocaine hydro- 65 contained in the oligonucleotide are arranged as set forth in 
chloride 1 (diamonds), deoxycorticosterone 21-glucoside 2 the following structure, wherein SEQ ID NO: 1-1 is the left 
(circles), dehydroisoandrosterone 3-sulfate sodium 3 hand sequence and SEQ ID NO:2 is the right hand sequence: 
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This invention further provides the instant composition, 
sitions, wherein the oligonucleotide comprises consecutive otides having the sequence set forth in SEQ ID NO:153, 
whereinSEQIDNO:153islocated3'toSEQIDNO:101 and 5, to SEQ IDNO:102, 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
~ 0 ~ 4 ,  wherein SEQ ID ~ 0 ~ 3  is located 51 to SEQ ID ~ 0 ~ 4 ,  NO:6, wherein SEQ ID NO:5 is located 5' to SEQ ID NO:6. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the o~igonuc~eotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID ~ 0 ~ 3  and SEQ ID ~ 0 ~ 4  contained in the forth in SEQ ID NO:5 and SEQ ID NO:6 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 1-1 is the left hand sequence structure, wherein SEQ ID NO: 103 is the left hand sequence 
and SEQ ID NO:4 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
The present invention further Provides the instant wherein the oligonucleotide comprises consecutive nucle- 
having the sequence set forth in SEQ ID No: 153, 55 wherein SEQ ID No:  153 is located 31 to SEQ ID No:  103 and 
having the sequences set forth in SEQ ID ~ 0 ~ 3  and SEQ ID 6o having the sequences set forth in SEQ ID and SEQ ID 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:5 and 5' wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:7 and 5' 
to SEQ ID NO:6. to SEQ ID NO:& 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 104 and SEQ 25 having the sequences set forth in SEQ ID NO: 105 and SEQ 
ID NO: 102, wherein SEQ ID NO: 104 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 105 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant osigonucle- 
wherein the oligonucleotide folds so that the sequences set 30 otide, wherein the oligonucleotide folds so that the sequences 
forth in SEQ ID NO:7 and SEQ ID NO:X contained in the set forth in SEQ ID NO: 105 and SEQ ID NO: 102 contained in 
oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 103 is the left hand sequence structure, wherein SEQ ID NO: 105 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
35 
40 
45 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 104 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 105 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:7 and SEQ ID 
NO:& wherein SEQ ID NO:7 is located 5' to SEQ ID NO:% 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:7 and SEQ ID NO:X contained in the 
oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:7 is the left hand sequence and 
SEQ ID NO:X is the right hand sequence: 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:9 and SEQ ID 
NO:10, whereinSEQIDNO:9islocated5'to SEQIDN0:lO. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:9 and SEQ ID NO:10 contained in the 
6 5  oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:105 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
60 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:9 and 5' wherein SEQ ID NO: 152 is located 3' to SEQ ID NO: 1 1 and 
to SEQ ID NO: 10. 5' to SEQ ID NO:12. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 106 and SEQ 25 having the sequences set forth in SEQ ID NO: 107 and SEQ 
ID NO: 102, wherein SEQ ID NO: 106 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 107 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant composition, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 106 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 107 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:106 is the left hand sequence structure: 
and SEQ ID NO: 102 is the right hand sequence: 
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/G.. . /T 
\)/T\ 40 
A 
\A 
T, &-A - A- T, / 
I 9-G-T-G' 
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This invention further provides the instant oligonucleotide, 
This invention further provides the instant composition, wherein the oligonucleotide folds so that the squence set forth 
wherein the oligonucleotide comprises consecutive nucle- in SEQ ID NO:107 SEQ ID NO:102 contained in the oligo- 
otides having the sequence set forth in SEQ ID NO: 153, nucleotide are arranged as set forth in the following strucrure, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 106 and 55 wherein SEQ ID NO: 107 is the left hand sequence and SEQ 
5' to SEQ ID NO:102. ID NO: 102 is the right hand sequence: 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 11 and SEQ ID having the sequences set forth in SEQ ID NO: 13 and SEQ ID 
NO:12, wherein SEQ ID N 0 : l l  is located 5' to SEQ ID 60 NO:14, wherein SEQ ID NO:13 is located 5' to SEQ ID 
NO:12. NO:14. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 1 1 and SEQ ID NO: 12 contained in the forth in SEQ ID NO: 13 and SEQ ID NO: 14 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 11 is the left hand sequence structure, wherein SEQ ID NO: 13 is the left hand sequence 
and SEQ ID NO: 12 is the right hand sequence: and SEQ ID NO: 14 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 31 to SEQ ID NO: 13 and wherein SEQ ID NO: 152 is located 3' to SEQ ID NO: 15 and 
5' to SEQ ID NO:14. 5' to SEQ ID NO:16. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 108 and SEQ 25 having the sequences set forth in SEQ ID NO: 109 and SEQ 
ID NO: 102, wherein SEQ ID NO: 108 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 109 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 108 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 109 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID N0:lOX is the left hand sequence structure, wherein SEQ ID NO:109 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 108 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 109 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 15 and SEQ ID having the sequences set forth in SEQ ID NO: 17 and SEQ ID 
NO:16, wherein SEQ ID NO:15 is located 5' to SEQ ID 60 NO:18, wherein SEQ ID NO:17 is located 5' to SEQ ID 
NO:16. NO:18. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 15 and SEQ ID NO: 16 contained in the forth in SEQ ID NO: 17 and SEQ ID NO: 18 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 15 is the left hand sequence structure, wherein SEQ ID NO: 17 is the left hand sequence 
and SEQ ID NO: 16 is the right hand sequence: and SEQ ID NO: 18 is the right hand sequence: 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:17 and 
5' to SEQ ID N0:lX. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 1 10 and SEQ 
ID NO: 102, wherein SEQ ID NO: 110 is located 5' to SEQ ID 
NO:102. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 1 10 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 110 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
5 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO: 19 and 
5' to SEQ ID NO:20. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
25 having the sequences set forth in SEQ ID NO: 1 11 and SEQ 
ID NO: 102, wherein SEQ ID NO: 11 1 is located 5' to SEQ ID 
NO:102. 
This invention further provides the instant oligonucleotide, 
3o wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 1 11 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 1 1 1 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
35 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 1 10 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 1 1 1 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 19 and SEQ ID having the sequences set forth in SEQ ID NO:21 and SEQ ID 
NO:20, wherein SEQ ID NO:19 is located 5' to SEQ ID 60 NO:22, wherein SEQ ID NO:21 is located 5' to SEQ ID 
NO:20. NO:22. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 19 and SEQ ID NO:20 contained in the forth in SEQ ID NO:21 and SEQ ID NO:22 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 19 is the left hand sequence structure, wherein SEQ ID NO: 1 is the left hand sequence and 
and SEQ ID NO:20 is the right hand sequence: SEQ ID NO:2 is the right hand sequence: 
19 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
This invention further provides the instant compos~t~on, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID otides having the sequence set forth in SEQ ID NO:153, 
whereinSEQ1DNo:153 is10cated3'to SEQ1DNo:112and 55 whereinSEQIDNo:153 islocated3tto SEQIDNO:113 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides This invention also provides a composition comprising an 
having the sequences set forth in SEQ ID NO:23 and SEQ ID oligonucleotide which comprises consecutive nucleotides 
~ 0 ~ 2 4 ,  wherein SEQ ID ~ 0 ~ 2 3  is located 51 to SEQ ID 6o having the sequences set forth in SEQ ID NO:25 and SEQ ID 
NO:24. NO:26, wherein SEQ ID NO:3 is located 5' to SEQ ID NO:4. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the o~igonuc~eotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID ~ 0 ~ 2 3  and SEQ ID ~ 0 ~ 2 4  contained in the forth in SEQ ID NO:25 and SEQ ID NO:26 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:23 is the left hand sequence structure, wherein SEQ ID NO:25 is the left hand sequence 
and SEQ ID NO:24 is the right hand sequence: and SEQ ID NO:26 is the right hand sequence: 
21 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 31 to SEQ ID NO:25 and wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:27 and 
5' to SEQ ID NO:26. 5' to SEQ ID NO:28. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 1 14 and SEQ 25 having the sequences set forth in SEQ ID NO: 1 15 and SEQ 
ID NO: 102, wherein SEQ ID NO: 1 14 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 11 5 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 1 14 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 1 15 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
Structure, wherein SEQ ID NO11 14 is the left hand sequence structure, wherein SEQ ID NO: 1 15 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
This invention further provides the instant compos~t~on, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID otides having the sequence set forth in SEQ ID NO:153, 
whereinSEQ1DNo:153 is10cated3'to SEQ1DNo:114and 55 whereinSEQIDNo:153 islocated3tto SEQIDNO:115 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides This invention also provides a composition comprising an 
having the sequences set forth in SEQ ID NO:27 and SEQ ID oligonucleotide which comprises consecutive nucleotides 
NO:28, wherein SEQ ID ~ 0 ~ 2 7  is located 51 to SEQ ID 6o having the sequences set forth in SEQ ID NO:29 and SEQ ID 
NO:28. NO:30, wherein SEQ ID NO:3 is located 5' to SEQ ID NO:4. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the o~igonuc~eotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID ~ 0 ~ 2 7  and SEQ ID NO128 contained in the forth in SEQ ID NO:29 and SEQ ID NO:30 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:27 is the left hand sequence structure, wherein SEQ ID NO:29 is the left hand sequence 
and SEQ ID NO:28 is the right hand sequence: and SEQ ID NO:304 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence Set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:29 and wherein SEQ ID ~ 0 ~ 1 5 2  is located 3' to SEQ ID ~ 0 ~ 3 1  and 
5' to SEQ ID NO:30. 5' to SEQ ID NO:32. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides o~igonuc~eotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO11 16 and SEQ 25 having the sequences set forth in SEQ ID NO: 1 17 and SEQ 
ID NO: 102, wherein SEQ ID NO: 116 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 117 is located 51 to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds SO that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO116 and SEQ ID NO:102 contained in forth in SEQ ID  NO:^ 17 and SEQ ID ~ 0 ~ 1 0 2  contained in 
the oligonucleotide are arranged as set forth in the following the o~igonuc~eotide are arranged as set forth in the following 
Structure, wherein SEQ ID NO11 16 is the left hand sequence structure, wherein SEQ ID NO: 1 17 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
This invention further provides the instant compos~t~on, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID otides having the sequence set forth in SEQ ID NO:153, 
whereinSEQ1DNo:153 is10cated3'to SEQ1DNo:116and 55 whereinSEQIDNo:153 islocated3tto SEQIDNO:117and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides This invention also provides a composition comprising an 
having the sequences set forth in SEQ ID NO:3 and SEQ ID oligonucleotide which comprises consecutive nucleotides 
~ 0 ~ 3 2 ,  wherein SEQ ID ~ 0 ~ 3  1 is located 51 to SEQ ID 6o having the sequences set forth in SEQ ID NO:33 and SEQ ID 
NO:32. NO:34, wherein SEQ ID NO:3 is located 5' to SEQ ID NO:4. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the o~igonuc~eotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID ~ 0 ~ 3 1  and SEQ ID ~ 0 ~ 3 2  contained in the forth in SEQ ID NO:33 and SEQ ID NO:34 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:31 is the left hand sequence structure, wherein SEQ ID NO:33 is the left hand sequence 
and SEQ ID NO:32 is the right hand sequence: and SEQ ID NO:34 is the right hand sequence: 
25 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:33 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:35 and 
5' to SEQ ID NO:34. 5' to SEQ ID NO:36. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 1 18 and SEQ 25 having the sequences set forth in SEQ ID NO: 1 19 and SEQ 
ID NO: 102, wherein SEQ ID NO: 1 18 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 11 9 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 3o wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 1 18 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 1 19 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 1 18 is the left hand sequence structure, wherein SEQ ID NO: 1 19 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 1 18 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 1 19 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:35 and SEQ ID having the sequences set forth in SEQ ID NO:37 and SEQ ID 
NO:36, wherein SEQ ID NO:35 is located 5' to SEQ ID 60 NO:38, wherein SEQ ID NO:37 is located 5' to SEQ ID 
NO:36. NO:38. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:35 and SEQ ID NO:36 contained in the forth in SEQ ID NO:37 and SEQ ID NO:38 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:35 is the left hand sequence structure, wherein SEQ ID NO:37 is the left hand sequence 
and SEQ ID NO:36 is the right hand sequence: and SEQ ID NO:38 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:37 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:39 and 
5' to SEQ ID NO:38. 5' to SEQ ID NO:40. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:120 and SEQ 25 having the sequences set forth in SEQ ID NO:121 and SEQ 
ID NO: 102, wherein SEQ ID NO: 120 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 121 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:120 and SEQ ID NO:102 contained in forth in SEQ ID NO:13 and SEQ ID NO: 14 contained in the 
the oligonucleotide are arranged as set forth in the following oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:120 is the left hand sequence structure, wherein SEQ ID NO: 13 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 14 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 120 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 121 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:39 and SEQ ID having the sequences set forth in SEQ ID NO:41 and SEQ ID 
NO:40, wherein SEQ ID NO:39 is located 5' to SEQ ID 60 NO:42, wherein SEQ ID NO:41 is located 5' to SEQ ID 
NO:40. NO:42. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:121 and SEQ ID NO:102 contained in forth in SEQ ID NO:41 and SEQ ID NO:42 contained in the 
the oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:121 is the left hand sequence structure, wherein SEQ ID NO:41 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO:42 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence Set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:41 and wherein SEQ ID ~ 0 ~ 1 5 2  is located 31 to SEQ ID ~ 0 ~ 4 3  and 
5' to SEQ ID NO:42. 5' to SEQ ID NO:44. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 123 and SEQ having the sequences set forth in SEQ ID NO: 122 and SEQ 25 ID NO: 102, wherein SEQ ID NO: 122 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 123 is located 5' to SEQ ID NO:102. 
NO:102. 
This invention further provides the instant oligonucleotide, 
wherein the o~igonuc~eotide folds so that the sequences set This invention further provides the instant oligonucleotide, 
forth in SEQ ID NO:122 and SEQ ID NO:102 contained in 30 wherein the oligonucleotide folds so that the sequences set 
the oligonucleotide are arranged as set forth in the following forth in SEQ ID and SEQ ID No:102 contained in 
wherein SEQ ID NO: 122 is the left hand sequence the oligonucleotide are arranged as set forth in the following 
and SEQ ID NO: 102 is the right hand sequence: structure, wherein SEQ ID NO:123 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 122 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 123 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:43 and SEQ ID having the sequences set forth in SEQ ID NO:45 and SEQ ID 
NO:44, wherein SEQ ID NO:43 is located 5' to SEQ ID 60 NO:46, wherein SEQ ID NO:45 is located 5' to SEQ ID 
NO:44. NO:46. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:43 and SEQ ID NO:44 contained in the forth in SEQ ID NO:119 and SEQ ID NO:102 contained in 
oligonucleotide are arranged as set forth in the following 65 the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:43 is the left hand sequence structure, wherein SEQ ID NO:45 is the left hand sequence 
and SEQ ID NO:44 is the right hand sequence: and SEQ ID NO:46 is the right hand sequence: 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:45 and 
5' to SEQ ID NO:46. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 124 and SEQ 
ID NO: 102, wherein SEQ ID NO: 124 is located 5' to SEQ ID 
NO:102. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 124 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:124 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
A'. . /l 
\ 
'C 
This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 124 and 
5' to SEQ ID NO:102. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:47 and SEQ ID 
NO:48, wherein SEQ ID NO:47 is located 5' to SEQ ID 
NO:48. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:47 and SEQ ID NO:48 contained in the 
oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:47 is the left hand sequence 
and SEQ ID NO:48 is the right hand sequence: 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:47 and 
5' to SEQ ID NO:48. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 125 and SEQ 
ID NO: 102, wherein SEQ ID NO: 125 is located 5' to SEQ ID 
NO:102. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:125 and SEQ ID NO:102 contained in 
the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:125 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
5' 
This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 125 and 
5' to SEQ ID NO:102. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:49 and SEQ ID 
NO:50, wherein SEQ ID NO:3 is located 5' to SEQ ID NO:4. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:49 and SEQ ID NO:50 contained in the 
oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:49 is the left hand sequence 
and SEQ ID NO:50 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:49 and wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:5 1 and 
5' to SEQ ID NO:50. 5' to SEQ ID NO:52. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:126 and SEQ 25 having the sequences set forth in SEQ ID NO:127 and SEQ 
ID NO: 102, wherein SEQ ID NO: 126 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 127 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 126 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 127 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:126 is the left hand sequence structure, wherein SEQ ID NO:127 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 126 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 127 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:5 1 and SEQ ID having the sequences set forth in SEQ ID NO:53 and SEQ ID 
NO:52, wherein SEQ ID NO:51 is located 5' to SEQ ID 60 NO:54, wherein SEQ ID NO:53 is located 5' to SEQ ID 
NO:52. NO:54. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:51 and SEQ ID NO:52 contained in the forth in SEQ ID NO:53 and SEQ ID NO:5554 contained in 
oligonucleotide are arranged as set forth in the following 65 the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:51 is the left hand sequence structure, wherein SEQ ID NO:53 is the left hand sequence 
and SEQ ID NO:52 is the right hand sequence: and SEQ ID NO:55 is the right hand sequence: 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:53 and 
5' to SEQ ID NO:54. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:128 and SEQ 
ID NO: 102, wherein SEQ ID NO: 128 is located 5' to SEQ ID 
NO:102. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 128 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:128 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 128 and 
5' to SEQ ID NO:102. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:55 and SEQ ID 
NO:56, wherein SEQ ID NO:55 is located 5' to SEQ ID 
NO:56. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:55 and SEQ ID NO:56 contained in the 
oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:55 is the left hand sequence 
and SEQ ID NO:56 is the right hand sequence: 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO:152 is located 3' to SEQ ID NO:55 and 
5' to SEQ ID NO:56. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 129 and SEQ 
ID NO: 102, wherein SEQ ID NO: 129 is located 5' to SEQ ID 
NO:102. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:129 and SEQ ID NO:102 contained in 
the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:129 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 129 and 
5' to SEQ ID NO:102. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:57 and SEQ ID 
NO:58, wherein SEQ ID NO:57 is located 5' to SEQ ID 
NO:58. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:57 and SEQ ID NO:58 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:57 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:59 and 
5' to SEQ ID NO:58. 5' to SEQ ID NO:60. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:130 and SEQ 25 having the sequences set forth in SEQ ID NO:131 and SEQ 
ID NO: 102, wherein SEQ ID NO: 130 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 13 1 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds SO that the sequences set 
forth in SEQ ID NO: 130 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 13 1 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 130 is the left hand sequence structure, wherein SEQ ID NO: 13 1 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 130 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 13 1 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:59 and SEQ ID having the sequences set forth in SEQ ID NO:61 and SEQ ID 
NO:60, wherein SEQ ID NO:59 is located 5' to SEQ ID 60 NO:62, wherein SEQ ID NO:61 is located 5' to SEQ ID 
NO:60. NO:62. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:59 and SEQ ID NO:60 contained in the forth in SEQ ID NO:61 and SEQ ID NO:62 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:59 is the left hand sequence structure, wherein SEQ ID NO:61 is the left hand sequence 
and SEQ ID NO:60 is the right hand sequence: and SEQ ID NO:62 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:61 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:63 and 
5' to SEQ ID NO:62. 5' to SEQ ID NO:64. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:132 and SEQ 25 having the sequences set forth in SEQ ID NO:133 and SEQ 
ID NO: 102, wherein SEQ ID NO: 132 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 133 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 3o wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 132 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 133 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:132 is the left hand sequence structure, wherein SEQ ID NO:133 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 132 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 133 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:63 and SEQ ID having the sequences set forth in SEQ ID NO:65 and SEQ ID 
NO:64, wherein SEQ ID NO:63 is located 5' to SEQ ID 60 NO:66, wherein SEQ ID NO:61 is located 5' to SEQ ID 
NO:64. NO:62. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:63 and SEQ ID NO:64 contained in the forth in SEQ ID NO:65 and SEQ ID NO:66 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:63 is the left hand sequence structure, wherein SEQ ID NO:65 is the left hand sequence 
and SEQ ID NO:642 is the right hand sequence: and SEQ ID NO:66 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:65 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:67 and 
5' to SEQ ID NO:66. 5' to SEQ ID NO:68. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:134 and SEQ 25 having the sequences set forth in SEQ ID NO:135 and SEQ 
ID NO: 102, wherein SEQ ID NO: 134 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 135 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 3o wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:134 and SEQ ID NO:102 contained in forth in SEQ ID NO:135 and SEQ ID NO:102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:134 is the left hand sequence structure, wherein SEQ ID NO:135 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 134 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 135 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:67 and SEQ ID having the sequences set forth in SEQ ID NO:69 and SEQ ID 
NO:68, wherein SEQ ID NO:67 is located 5' to SEQ ID 60 NO:70, wherein SEQ ID NO:69 is located 5' to SEQ ID 
NO:68. NO:70. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:67 and SEQ ID NO:68 contained in the forth in SEQ ID NO:69 and SEQ ID NO:70 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:67 is the left hand sequence structure, wherein SEQ ID NO:69 is the left hand sequence 
and SEQ ID NO:68 is the right hand sequence: and SEQ ID NO:70 is the right hand sequence: 
\ .--T 
A' \ 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:69 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:71 and 
5' to SEQ ID NO:70. 5' to SEQ ID NO:72. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:136 and SEQ 25 having the sequences set forth in SEQ ID NO:137 and SEQ 
ID NO: 102, wherein SEQ ID NO: 136 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 137 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:136 and SEQ ID NO:102 contained in forth in SEQ ID NO:137 and SEQ ID NO:102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:136 is the left hand sequence structure, wherein SEQ ID NO:137 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 136 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 137 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:71 and SEQ ID having the sequences set forth in SEQ ID NO:73 and SEQ ID 
NO:72, wherein SEQ ID NO:71 is located 5' to SEQ ID 60 NO:74, wherein SEQ ID NO:73 is located 5' to SEQ ID 
NO:72. NO:74. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:71 and SEQ ID NO:72 contained in the forth in SEQ ID NO:73 and SEQ ID NO:74 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:72 is the left hand sequence structure, wherein SEQ ID NO:73 is the left hand sequence 
and SEQ ID NO:72 is the right hand sequence: and SEQ ID NO:74 is the right hand sequence: 
\ .--T 
A' \ 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:73 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:75 and 
5' to SEQ ID NO:74. 5' to SEQ ID NO:76. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:138 and SEQ 25 having the sequences set forth in SEQ ID NO:139 and SEQ 
ID NO: 102, wherein SEQ ID NO: 138 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 139 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:138 and SEQ ID NO:102 contained in forth in SEQ ID NO:139 and SEQ ID NO:102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:138 is the left hand sequence structure, wherein SEQ ID NO:139 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 138 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 139 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:75 and SEQ ID having the sequences set forth in SEQ ID NO:77 and SEQ ID 
NO:76, wherein SEQ ID NO:75 is located 5' to SEQ ID 60 NO:78, wherein SEQ ID NO:77 is located 5' to SEQ ID 
NO:76. NO:78. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:75 and SEQ ID NO:76 contained in the forth in SEQ ID NO:77 and SEQ ID NO:78 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:75 is the left hand sequence structure, wherein SEQ ID NO:77 is the left hand sequence 
and SEQ ID NO:76 is the right hand sequence: and SEQ ID NO:78 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:77 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:79 and 
5' to SEQ ID NO:7X. 5' to SEQ ID N0:XO. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:140 and SEQ 25 having the sequences set forth in SEQ ID NO:141 and SEQ 
ID NO: 102, wherein SEQ ID NO: 140 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 141 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds SO that the sequences set 
forth in SEQ ID NO:140 and SEQ ID NO:102 contained in forth in SEQ ID NO:141 and SEQ ID NO:102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:140 is the left hand sequence structure, wherein SEQ ID NO:141 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 140 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 141 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:79 and SEQ ID having the sequences set forth in SEQ ID NO:X1 and SEQ ID 
NO:XO, wherein SEQ ID NO:79 is located 5' to SEQ ID 60 NO:X2, wherein SEQ ID NO:X1 is located 5' to SEQ ID 
N0:XO. NO:X2. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:79 and SEQ ID N0:XO contained in the forth in SEQ ID NO:X1 and SEQ ID NO:X2 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:79 is the left hand sequence structure, wherein SEQ ID NO:X1 is the left hand sequence 
and SEQ ID N0:XO is the right hand sequence: and SEQ ID NO:X2 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:X1 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:X3 and 
5' to SEQ ID NO:X2. 5' to SEQ ID NO:X4. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 142 and SEQ 25 having the sequences set forth in SEQ ID NO: 143 and SEQ 
ID NO: 102, wherein SEQ ID NO: 142 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 143 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 3o wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 142 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 143 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:142 is the left hand sequence structure, wherein SEQ ID NO:143 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 142 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 143 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:X3 and SEQ ID having the sequences set forth in SEQ ID NO:X5 and SEQ ID 
NO:X4, wherein SEQ ID NO:X3 is located 5' to SEQ ID 60 NO:X6, wherein SEQ ID NO:X5 is located 5' to SEQ ID 
NO:X4. NO:X6. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:X3 and SEQ ID NO:X4 contained in the forth in SEQ ID NO:X5 and SEQ ID NO:X6 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:X3 is the left hand sequence structure, wherein SEQ ID NO:X5 is the left hand sequence 
and SEQ ID NO:X4 is the right hand sequence: and SEQ ID NO:X6 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 2~ otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:X5 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:X7 and 
5' to SEQ ID NO:X6. 5' to SEQ ID N0:XX. 
This invention further provides the instant oligonucleotide, This invention also provides a composition comprising an 
wherein the oligonucleotide folds so that the sequences set oligonucleotide which comprises consecutive nucleotides 
forth in SEQ ID NO: 144 and SEQ ID NO: 102 contained in 25 having the sequences set forth in SEQ ID NO: 145 and SEQ 
the oligonucleotide are arranged as set forth in the following ID NO: 102, wherein SEQ ID NO: 145 is located 5' to SEQ ID 
structure, wherein SEQ ID NO:144 is the left hand sequence NO:102. 
and SEQ ID NO: 102 is the right hand sequence: This invention further provides the instant oligonucleotide, 
This invention further provides the instant composition, 3o wherein the oligonucleotide folds so that the sequences set 
wherein the oligonucleotide folds so that the sequences set forth in SEQ ID NO:145 and SEQ ID NO:102 contained in 
forth in SEQ ID NO: 144 and SEQ ID NO: 102 contained in the oligonucleotide are arranged as set forth in the following 
the oligonucleotide are arranged as set forth in the following structure, wherein SEQ ID NO: 145 is the left hand sequence 
structure: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 144 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 145 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:X7 and SEQ ID having the sequences set forth in SEQ ID NO:X9 and SEQ ID 
NO:XX, wherein SEQ ID NO:X7 is located 5' to SEQ ID 60 NO:90, wherein SEQ ID NO:X9 is located 5' to SEQ ID 
N0:XX. NO:90. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:X7 and SEQ ID N0:XX contained in the forth in SEQ ID NO:X9 and SEQ ID NO:90 contained in the 
oligonucleotide are arranged as set forth in the following 65 oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:X7 is the left hand sequence structure, wherein SEQ ID NO:X9 is the left hand sequence 
and SEQ ID N0:XX is the right hand sequence: and SEQ ID NO:90 is the right hand sequence: 
\ .--T 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:X9 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:91 and 
5' to SEQ ID NO:90. 5' to SEQ ID NO:92. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:145 and SEQ 25 having the sequences set forth in SEQ ID NO:147 and SEQ 
ID NO: 102, wherein SEQ ID NO: 146 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 147 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 146 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 147 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:146 is the left hand sequence structure, wherein SEQ ID NO:147 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 146 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 147 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:91 and SEQ ID having the sequences set forth in SEQ ID NO:93 and SEQ ID 
NO:92, wherein SEQ ID NO:91 is located 5' to SEQ ID 60 NO:94, wherein SEQ ID NO:93 is located 5' to SEQ ID 
NO:92. NO:94. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:91 and SEQ ID NO:92 contained in the forth in SEQ ID NO:93 and SEQ ID NO:94 contained in the 
oligonucleotide are arranged as set forth in the following 6 5  oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:91 is the left hand sequence structure, wherein SEQ ID NO:93 is the left hand sequence 
and SEQ ID NO:92 is the right hand sequence: and SEQ ID NO:94 is the right hand sequence: 
\ .--T 
A' \ 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 20 otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:94 and wherein SEQ ID NO:152 is located 3' to SEQ ID NO:95 and 
5' to SEQ ID NO:94. 5' to SEQ ID NO:96. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:148 and SEQ 25 having the sequences set forth in SEQ ID NO:149 and SEQ 
ID NO: 102, wherein SEQ ID NO: 148 is located 5' to SEQ ID ID NO: 102, wherein SEQ ID NO: 149 is located 5' to SEQ ID 
NO:102. NO:102. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 30 wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 148 and SEQ ID NO: 102 contained in forth in SEQ ID NO: 149 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:148 is the left hand sequence structure, wherein SEQ ID NO:149 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:153, otides having the sequence set forth in SEQ ID NO:153, 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 148 and 55 wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 149 and 
5' to SEQ ID NO:102. 5' to SEQ ID NO:102. 
This invention also provides a composition comprising an This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO:95 and SEQ ID having the sequences set forth in SEQ ID NO:97 and SEQ ID 
NO:96, wherein SEQ ID NO:95 is located 5' to SEQ ID 60 NO:98, wherein SEQ ID NO:97 is located 5' to SEQ ID 
NO:96. NO:98. 
This invention further provides the instant oligonucleotide, This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO:95 and SEQ ID NO:96 contained in the forth in SEQ ID NO:97 and SEQ ID NO:98 contained in the 
oligonucleotide are arranged as set forth in the following 6 5  oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO:95 is the left hand sequence structure, wherein SEQ ID NO:97 is the left hand sequence 
and SEQ ID NO:96 is the right hand sequence: and SEQ ID NO:98 is the right hand sequence: 
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This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO: 152 is located 3' to SEQ ID NO:97 and 
5' to SEQ ID NO:98. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
having the sequences set forth in SEQ ID NO: 150 and SEQ 
ID NO: 102, wherein SEQ ID NO: 150 is located 5' to SEQ ID 
NO:102. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
forth in SEQ ID NO: 150 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 150 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
5 
10 
15 
This invention further provides the instant composition, 
wherein the oligonucleotide comprises consecutive nucle- 
2o otides having the sequence set forth in SEQ ID NO:152, 
wherein SEQ ID NO:152 is located 3' to SEQ ID NO:99 and 
5' to SEQ ID NO: 100. 
This invention also provides a composition comprising an 
oligonucleotide which comprises consecutive nucleotides 
25 having the sequences set forth in SEQ ID NO: 15 1 and SEQ 
ID NO: 102, wherein SEQ ID NO: 15 1 is located 5' to SEQ ID 
NO:102. 
This invention further provides the instant oligonucleotide, 
wherein the oligonucleotide folds so that the sequences set 
30 forth in SEQ ID NO: 151 and SEQ ID NO: 102 contained in 
the oligonucleotide are arranged as set forth in the following 
structure, wherein SEQ ID NO: 15 1 is the left hand sequence 
and SEQ ID NO: 102 is the right hand sequence: 
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This invention further provides the instant composition, 
This invention further provides the instant composition, wherein the oligonucleotide comprises consecutive nucle- 
wherein the oligonucleotide comprises consecutive nucle- otides having the sequence set forth in SEQ ID NO:153, 
otides having the sequence set forth in SEQ ID NO: 153, wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 15 1 and 
wherein SEQ ID NO: 153 is located 3' to SEQ ID NO: 150 and 55 5 1 to SEQ ID NO: 102. 
5' to SEQ ID NO:102. The present invention further provides the instant oligo- 
This invention also provides a composition comprising an nucleotides, wherein the oligonucleotide comprises a phos- 
oligonucleotide which comprises consecutive nucleotides phorothioate group. 
having the sequences set forth in SEQ ID NO:99 and SEQ ID The present invention further provides the instant oligo- 
NO: 100, wherein SEQ ID NO:99 is located 5' to SEQ ID 60 nucleotides, wherein the oligonucleotides further comprise a 
NO: 100. fluorophore attached to a sulfur of the phosphorothioate 
This invention further provides the instant oligonucleotide, group. 
wherein the oligonucleotide folds so that the sequences set The present invention further provides the instant oligo- 
forth in SEQ ID NO:99 and SEQ ID NO: 100 contained in the nucleotides, wherein the fluorophore is chosen from the 
oligonucleotide are arranged as set forth in the following 65 group consisting of fluorescein, Oregon Green, JOE, HEX, 
structure, wherein SEQ ID NO:99 is the left hand sequence TETAlexa Fluor, Rhodamine Green, eosin, erythroscein, and 
and SEQ ID NO: 100 is the right hand sequence: BODIPY related dye. 
US 7,470s 16 B2 
59 
The present invention further provides the instant oligo- 
nucleotides, wherein the fluorophore is a fluorescein deriva- 
tive. 
The present invention further provides the instant oligo- 
nucleotides, wherein the fluorescein derivative comprises a 
substituent attached to an aromatic carbon of a fluorescein. 
The present invention further provides the instant oligo- 
nucleotides, wherein the oligonucleotide is 25 to 120 nucle- 
otides in length. 
This invention also provides a method of detecting an 
analyte in a solution comprising: 
(a) providing a composition comprising an oligonucleotide 
and a fluorescent moiety attached to the oligonucleotide, 
wherein the oligonucleotide undergoes a conforma- 
tional change upon contact with the analyte and the 
fluorescent moiety undergoes a change of fluorescence 
upon the conformational change; 
(b) quantitating the fluorescence of the fluorescent moiety 
of the composition in the absence of the analyte; 
(c) subsequently contacting the composition with the solu- 
tion containing the analyte; 
(d) quantitating the fluorescence of the fluorescent moiety 
of the composition in contact with the solution contain- 
ing the analyte; and 
(e) comparing the fluorescence quantitated in step (b) with 
that quantitated in step (d), 
wherein a change in the fluorescence quantitated in step (d) 
as comparedwith the fluorescence quantitated in step (b) 
indicates that the analyte is present in the solution. 
This invention also provides a method of determining 
whether an amount of an analyte in a first solution is different 
to that of an amount of the analyte in a second solution 
comprising: 
(a) providing a composition comprising an oligonucleotide 
and a fluorescent moiety attached to the oligonucleotide, 
wherein the oligonucleotide undergoes a conforma- 
tional change upon contact with the analyte and the 
fluorescent moiety undergoes a change of fluorescence 
upon the conformational change; 
(b) contacting the composition with the first solution con- 
taining the analyte; 
(c) quantitating the fluorescence of the fluorescent moiety 
of the composition; 
(d) washing the composition to remove the first solution; 
(e) contacting the composition with the second solution 
containing the analyte; 
(f) quantitating the fluorescence of the fluorescent moiety 
of the composition; and 
(g) comparing the fluorescence quantitated in step (f) with 
that quantitated in step (c), 
wherein a change in the fluorescence quantitated in step (f) 
as compared with the fluorescence quantitatedin step (c) 
indicates that the amount of the analyte in the first solu- 
tion is different to the amount of the analyte in the 
second solution. 
This invention also provides a method of quantitating an 
(a) providing a composition comprising an oligonucleotide 
and a fluorescent moiety attached to the oligonucleotide, 
wherein the oligonucleotide undergoes a conforma- 
tional change upon contact with the analyte and the 
fluorescent moiety undergoes a change of fluorescence 
upon the conformational change; 
(b) providing a predetermined relationship between the 
fluorescent moiety fluorescence and the analyte concen- 
tration; 
analyte in a solution comprising: 
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(c) contacting the composition with the solution containing 
the analyte; 
(d) quantitating the fluorescence of the fluorescent moiety 
of the composition in contact with the solution contain- 
ing the analyte; 
(e) quantitating the analyte in the solution from the fluo- 
rescence quantitated in step (d) and the predetermined 
relationship provided in step (b). 
This invention also provides the instant methods, wherein 
two or more compositions are present. 
This invention also provides a method of determining 
whether a first solution comprising a first analyte has an 
analyte composition different to that of a second solution 
comprising a second analyte comprising: 
(a) providing a first composition comprising a first oligo- 
nucleotide and a first fluorescent moiety attached to the 
first oligonucleotide, and a second composition com- 
prising a second oligonucleotide and a second fluores- 
cent moiety attached to the second oligonucleotide, 
wherein each of the first and second oligonucleotides 
undergoes a conformational change upon contact with 
the first analyte and upon contact with the second ana- 
lyte, and each of the fluorescent moieties undergoes a 
change of fluorescence upon the conformational change 
of the oligonucleotides upon contact with the first ana- 
lyte and upon contact with the second analyte; 
(b) contacting the first composition and second composi- 
tion with the first solution containing the first analyte; 
(c) quantitating the fluorescence of each of the fluorescent 
moieties; 
(d) washing to remove the first solution; 
(e) contacting the first composition and second composi- 
tion with the second solution containing the second ana- 
lyte; 
(f) quantitating the fluorescence of each of the fluorescent 
moieties; and 
(g) comparing the fluorescence quantitated in step (f) with 
that quantitated in step (c), 
wherein a change in the fluorescence quantitated in step (f) 
as compared with the fluorescence quantitated in step (c) 
indicates that the first solution containing the first ana- 
lyte has an analyte composition different to that of the 
second solution containing the second analyte. 
This invention also provides the instant methods, wherein 
the oligonucleotide comprises a phosphorothioate group and 
a fluorescence moiety attached to the sulfur of the phospho- 
rothioate group. 
This invention also provides the instant methods, wherein 
the first solution is a sample derived from a subject and the 
second solution is a reference solution. 
This invention also provides the instant methods, wherein 
the second solution is a sample derived from a subject and the 
first solution is a reference solution. 
This invention also provides the instant methods, further 
comprising providing in step (a) a third composition compris- 
ing a third oligonucleotide and a fluorescent moiety attached 
to the third oligonucleotide, wherein the third oligonucleotide 
undergoes a conformational change upon contact with the 
first analyte and upon contact with the second analyte, and 
which fluorescent moiety undergoes a change of fluorescence 
upon the conformational change. 
This invention also provides the instant methods, further 
comprising providing in step (a) a fourth composition com- 
prising a fourth oligonucleotide and a fluorescent moiety 
attached to the fourth oligonucleotide, wherein the fourth 
oligonucleotide undergoes a conformational change upon 
contact with the first analyte and upon contact with the second 
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analyte, and which fluorescent moiety undergoes a change of NO:33 and 34, or SEQ ID NO:35 and 36, or SEQ ID NO:37 
fluorescence upon the conformational change. and 38, or SEQ ID NO:39 and 40, or SEQ ID NO:41 and 42, 
This invention also provides the instant methods, further or SEQ ID NO:43 and 44, or SEQ ID NO:45 and 46, or SEQ 
comprising providing an xth composition comprising an ID NO:47 and 48, or SEQ ID NO:49 and 50, or SEQ ID 
xtholigonucleotide and a fluorescent moiety attached to the 5 NO:51 and 52, or SEQ ID NO:53 and 54, or SEQ ID NO:55 
oligonucleotide, wherein x is between 4 and 3000, wherein and 56, or SEQ ID NO:57 and 58, or SEQ ID NO:59 and 60, 
the xtholigonucleotide undergoes a conformational change or SEQ ID NO:61 and 62, or SEQ ID NO:63 and 64, or SEQ 
upon contact with the first analyte and upon contact with the ID NO:65 and 66, or SEQ ID NO:67 and 68, or SEQ ID 
second analyte, and which fluorescent moiety undergoes a NO:69 and 70, or SEQ ID NO:71 and 72, or SEQ ID NO:73 
change of fluorescence upon the conformational change. i o  and 74, or SEQ ID NO:75 and 76, or SEQ ID NO:77 and 78, 
This invention also provides the instant methods, wherein or SEQ ID NO:79 and 80, or SEQ ID NO:81 and 82, or SEQ 
two or more analytes are present in each solution and each ID NO:83 and 84, or SEQ ID NO:85 and 86, or SEQ ID 
oligonucleotide undergoes a conformational change upon NO:87 and 88, or SEQ ID NO:89 and 90, or SEQ ID NO:91 
contact with each of the 2 or more analytes. and 92, or SEQ ID NO:93 and 94, or SEQ ID NO:95 and 96, 
This invention also provides the instant methods, further 15 or SEQ ID NO:97 and 98, or SEQ ID NO:99 and 100, wherein 
comprising providing a predetermined relationship between the first mentioned sequence of each pair is located 5' to the 
fluorescence and analyte concentration for each analyte and second mentioned sequence. This invention also provides 
determining the concentration of each analyte from the pre- compositions comprising an oligonucleotide comprising 
determined relationship. consecutive nucleotides containing the sequences set forth in 
This invention also provides the instant methods, wherein 20 SEQ ID NO:102 and 101, or SEQ ID NO:102 and 103, or 
the solution is a sample of a bodily fluid obtained from a SEQ ID NO:102 and 104, or SEQ ID NO:102 and 105, or 
subject. SEQ ID NO:102 and 106, or SEQ ID NO:102 and 107, or 
This invention also provides the instant methods, wherein SEQ ID NO:102 and 108, or SEQ ID NO:102 and 109, or 
the bodily fluid is blood, a blood product, urine, a urine SEQ ID NO:102 and 110, or SEQ ID NO:102 and 111, or 
product, saliva, a saliva product, or sweat. 25 SEQ ID NO:102 and 112, or SEQ ID NO:102 and 113, or 
This invention also provides the instant methods, wherein SEQ ID NO:102 and 114, or SEQ ID NO:102 and 115, or 
the subject is mammalian. SEQ ID NO:102 and 116, or SEQ ID NO:102 and 117, or 
This invention also provides the instant methods, wherein SEQ ID NO:102 and 118, or SEQ ID NO:102 and 119, or 
the subject is human. SEQ ID NO:102 and 120, or SEQ ID NO:102 and 121, or 
This invention also provides the instant methods, wherein 30 SEQ ID NO:102 and 122, or SEQ ID NO:102 and 123, or 
the oligonucleotides have any of the following structures: SEQ ID NO:102 and 124, or SEQ ID NO:102 and 125, or 
This invention also provides the instant methods, wherein SEQ ID NO:102 and 126, or SEQ ID NO:102 and 127, or 
each analyte is a molecule. SEQ ID NO:102 and 128, or SEQ ID NO:102 and 129, or 
This invention also provides the instant methods, wherein SEQ ID NO:102 and 130, or SEQ ID NO:102 and 131, or 
the first and second analyte are molecules having the same 35 SEQ ID NO:102 and 132, or SEQ ID NO:102 and 133, or 
molecular structure. SEQ ID NO:102 and 134, or SEQ ID NO:102 and 135, or 
This invention also provides the instant methods, wherein SEQ ID NO:102 and 136, or SEQ ID NO:102 and 137, or 
the first and second analyte have a different molecular struc- SEQ ID NO:102 and 138, or SEQ ID NO:102 and 139, or 
ture. SEQ ID NO:102 and 140, or SEQ ID NO:102 and 141, or 
This invention also provides the instant methods, wherein 40 SEQ ID NO:102 and 142, or SEQ ID NO:102 and 143, or 
the molecule is a steroid or an alkaloid. SEQ ID NO:102 and 144, or SEQ ID NO:102 and 145, or 
This invention also provides the instant methods, wherein SEQ ID NO:102 and 146, or SEQ ID NO:102 and 147, or 
the steroid has a cholestane, androstane, or pregnane core. SEQ ID NO:102 and 148, or SEQ ID NO:102 and 149, or 
This invention also provides the instant methods, wherein SEQ ID NO: 102 and 150, or SEQ ID NO: 102 and 15 1, 
the steroid is bile acids, 17-keto steroid, 17-hydroxycorticos- 45 wherein the second mentioned sequence of each pair is 
teroid analog, cortisone, corticosterone or a derivative located 5' to the first mentioned sequence. 
thereof. This invention further provides the instant oligonucle- 
This invention also provides the instant methods, wherein otides, wherein the oligonucleotide folds so that the 
the analyte is brucine, strychnine or a fullerene C60. sequences set forth in SEQ ID NO: 1 and 2 contained in the 
This invention also provides the instant methods, wherein 50 oligonucleotide are arranged as set forth in structure 2 of FIG. 
the first solution contains more than one analyte. 1, so that the sequences set forth in SEQ ID NO:3 and 4 
This invention also provides the instant methods, wherein contained in the oligonucleotide are arranged as set forth in 
the second solution contains more than one analyte. structure 3 of FIG. 1, so that the sequences set forth in SEQ ID 
This invention also provides the instant methods, wherein NO:5 and 6 contained in the oligonucleotide are arranged as 
at least one composition is attached to a solid surface. 55 set forth in structure 4 of FIG. 1, so that the sequences set forth 
This invention also provides the instant methods, wherein in SEQ ID NO:7 and 8 contained in the oligonucleotide are 
the solid surface is a microchip, optical fiber, glass, a bead, a arranged as set forth in structure 5 of FIG. 1, so that the 
multi-well plate, a column, a membrane, or a matrix. sequences set forth in SEQ ID NO:9 and 10 contained in the 
This invention also provides compositions comprising an oligonucleotide are arranged as set forth in structure 6 of FIG. 
oligonucleotide comprising consecutivenucleotides contain- 60 1, so that the sequences set forth in SEQ ID NO:13 and 14 
ing the sequences set forth in SEQ ID NO: 1 and 2, or SEQ ID contained in the oligonucleotide are arranged as set forth in 
NO:3 and 4, or SEQ ID NO:5 and 6, or SEQ ID NO:7 and 8, structure 7 of FIG. 1, so that the sequences set forth in SEQ ID 
or SEQ ID NO:9 and 10 or SEQ ID NO: 13 and 14, or SEQ ID NO: 15 and 16 contained in the oligonucleotide are arranged 
NO: 15 and 16, or SEQ ID NO: 17 and 18, or SEQ ID NO: 19 as set forth in structure 8 of FIG. 1, so that the sequences set 
and 20, or SEQ ID NO:21 and 22, or SEQ ID NO:23 and 24, 65 forth in SEQ ID NO:17 and 18 contained in the oligonucle- 
or SEQ ID NO:25 and 26, or SEQ ID NO:27 and 28, or SEQ otide are arranged as set forth in structure 9 of FIG. 1, so that 
ID NO:29 and 30, or SEQ ID NO:31 and 32, or SEQ ID the sequences set forth in SEQ ID NO: 19 and 20 contained in 
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the oligonucleotide are arranged as set forth in structure 10 of ID NO:77 and 78 contained in the oligonucleotide are 
FIG. 1, so that the sequences set forth in SEQ ID NO:21 and arranged as set forth in structure 39 of FIG. 4, so that the 
22 contained in the oligonucleotide are arranged as set forth in sequences set forth in SEQ ID NO:79 and 80 contained in the 
structure 11 of FIG. 2, so that the sequences set forth in SEQ oligonucleotide are arranged as set forth in structure 40 of 
ID NO:23 and 24 contained in the oligonucleotide are 5 FIG. 4, so that the sequences set forth in SEQ ID NO:81 and 
arranged as set forth in structure 12 of FIG. 2, so that the 82 containedin the oligonucleotide are arranged as set forth in 
sequences set forth in SEQ ID NO:25 and 26 contained in the structure 41 of FIG. 5, so that the sequences set forth in SEQ 
oligonucleotide are arranged as set forth in structure 13 of ID NO:83 and 84 contained in the oligonucleotide are 
FIG. 2, so that the sequences set forth in SEQ ID NO:27 and arranged as set forth in structure 42 of FIG. 5, so that the 
28 contained in the oligonucleotide are arranged as set forth in i o  sequences set forth in SEQ ID NO: 85 and 86 contained in the 
structure 14 of FIG. 2, so that the sequences set forth in SEQ oligonucleotide are arranged as set forth in structure 43 of 
ID NO:29 and 30 contained in the oligonucleotide are FIG. 5, so that the sequences set forth in SEQ ID NO:87 and 
arranged as set forth in structure 15 of FIG. 2, so that the 88 containedin the oligonucleotide are arranged as set forth in 
sequences set forth in SEQ ID NO:3 1 and 32 contained in the structure 44 of FIG. 5, so that the sequences set forth in SEQ 
oligonucleotide are arranged as set forth in structure 16 of 15 ID NO:89 and 90 contained in the oligonucleotide are 
FIG. 2, so that the sequences set forth in SEQ ID NO:33 and arranged as set forth in structure 45 of FIG. 5, so that the 
34 contained in the oligonucleotide are arranged as set forth in sequences set forth in SEQ ID NO: 9 1 and 92 contained in the 
structure 17 of FIG. 2, so that the sequences set forth in SEQ oligonucleotide are arranged as set forth in structure 46 of 
ID NO:35 and 36 contained in the oligonucleotide are FIG. 5, so that the sequences set forth in SEQ ID NO:93 and 
arranged as set forth in structure 18 of FIG. 2, so that the 20 94 containedin the oligonucleotide are arranged as set forth in 
sequences set forth in SEQ ID NO:37 and 38 contained in the structure 47 of FIG. 5, so that the sequences set forth in SEQ 
oligonucleotide are arranged as set forth in structure 19 of ID NO:95 and 96 contained in the oligonucleotide are 
FIG. 2, so that the sequences set forth in SEQ ID NO:39 and arranged as set forth in structure 48 of FIG. 5, so that the 
40 containedin the oligonucleotide are arranged as set forth in sequences set forth in SEQ ID NO:97 and 98 contained in the 
structure 20 of FIG. 2, so that the sequences set forth in SEQ 25 oligonucleotide are arranged as set forth in structure 49 of 
ID NO:41 and 42 contained in the oligonucleotide are FIG. 5, so that the sequences set forth in SEQ ID NO:99 and 
arranged as set forth in structure 21 of FIG. 3, so that the 100 contained in the oligonucleotide are arranged as set forth 
sequences set forth in SEQ ID NO:43 and 44 contained in the in structure 50 of FIG. 5. 
oligonucleotide are arranged as set forth in structure 22 of This invention further provides any of the instant oligo- 
FIG. 3, so that the sequences set forth in SEQ ID NO:45 and 30 nucleotides further comprising consecutive nucleotides hav- 
46 contained in the oligonucleotide are arranged as set forth in ing the sequence set forth in SEQ ID NO: 152, wherein SEQ 
structure 23 of FIG. 3, so that the sequences set forth in SEQ ID NO: 152 is located 3’ to the first mentioned sequence of 
ID NO:47 and 48 contained in the oligonucleotide are each pair, and located 5‘ to the second mentioned sequence of 
arranged as set forth in structure 24 of FIG. 3, so that the each pair. This invention further provides any of the instant 
sequences set forth in SEQ ID NO:49 and 50 contained in the 35 oligonucleotides further comprising consecutive nucleotides 
oligonucleotide are arranged as set forth in structure 25 of having the sequence set forth in SEQ ID NO:153, wherein 
FIG. 3, so that the sequences set forth in SEQ ID NO:51 and SEQ ID NO: 153 is located 5‘ to the first mentioned sequence 
52 contained in the oligonucleotide are arranged as set forth in of each pair, and located 3’ to the second mentioned sequence 
structure 26 of FIG. 3, so that the sequences set forth in SEQ of each pair. 
ID NO:53 and 54 contained in the oligonucleotide are 40 This invention further provides any of the instant oligo- 
arranged as set forth in structure 27 of FIG. 3, so that the nucleotides, further comprising a phosphorothioate bond at 
sequences set forth in SEQ ID NO:55 and 56 contained in the the position marked “F” in structures 1-10 of FIG. 1, struc- 
oligonucleotide are arranged as set forth in structure 28 of tures 11 to 20 of FIG. 2, structures 21 to 30 of FIG. 3, 
FIG. 3, so that the sequences set forth in SEQ ID NO:57 and structures 31 to 40 of FIG. 4, and structures 41 to 50 of FIG. 
58containedintheoligonucleotidearearrangedas set forthin 45 5, structures 51 to 60 of FIG. 6, structures 61 to 70 of FIG. 7, 
structure 29 of FIG. 3, so that the sequences set forth in SEQ structures 71 to 80 of FIG. 8, structures 81 to 90 of FIG. 9, and 
ID NO:59 and 60 contained in the oligonucleotide are structures 91 to 100 of FIG. 10. Alternatively, bases in the 
arranged as set forth in structure 30 of FIG. 3, so that the oligonucleotide sequences can be derivatized with fluores- 
sequences set forth in SEQ ID NO:61 and 62 contained in the cent moieties. For example, a uridine within the hydrophobic 
oligonucleotide are arranged as set forth in structure 31 of 50 pocket derivatized with a fluorescent group, (9) and (12), 
FIG. 4, so that the sequences set forth in SEQ ID NO:63 and showedfluorescenceresponses inthepresence ofcocaineand 
64 containedin the oligonucleotide are arranged as set forth in various steroids. 
structure 30 of FIG. 3, so that the sequences set forth in SEQ This invention further provides the instant methods 
ID NO:65 and 66 contained in the oligonucleotide are wherein the compositions comprising oligonucleotides are 
arranged as set forth in structure 33 of FIG. 4, so that the 55 non-specific in binding or interacting with analytes. In one 
sequences set forth in SEQ ID NO:67 and 68 contained in the embodiment the non specific binding is cross-reactive: i.e. the 
oligonucleotide are arranged as set forth in structure 34 of oligonucleotide composition or “sensor” has more a 20% 
FIG. 4, so that the sequences set forth in SEQ ID NO:69 and change in the fluorescence of the fluorescent moiety upon 
70 contained in the oligonucleotide are arranged as set forth in binding or interacting with more than one steroid or alkaloid 
structure 35 of FIG. 4, so that the sequences set forth in SEQ 60 analyte in the concentration ranges from 1 micromolar to 
ID NO:71 and 72 contained in the oligonucleotide are 1000 micromolar (1 millimolar). In an embodiment the oli- 
arranged as set forth in structure 36 of FIG. 4, so that the gonucleotide composition or “sensor” has differential cross- 
sequences set forth in SEQ ID NO:73 and 74 contained in the reactivity: i.e. a group of two or more oligonucleotide com- 
oligonucleotide are arranged as set forth in structure 37 of positionsisensors having different slopes andor different 
FIG. 4, so that the sequences set forth in SEQ ID NO:75 and 65 inflection points of dose-response curves for steroids or alka- 
76 containedin the oligonucleotide are arranged as set forth in loid analytes which cause a change in fluorescence in the 
structure 38 of FIG. 4, so that the sequences set forth in SEQ concentration from 1 micromolar to 1000 micromolar. In one 
US 7,4703 16 B2 
65 66 
embodiment the fluorescence change is between 1 and 5%. In rable by affinity chromatography. These diastereomers inter- 
another embodiment the fluorescence change is between 5 act differently with analytes, but the nature of crossreacive 
and 15%. In another embodiment the fluorescence change is arrays makes this additional complexity acceptable. As dis- 
between 15 and 25%. In another embodiment the fluores- cussed herein the mixture of diastereomers will be referred to 
cence change is between 25 and 35%. In another embodiment 5 as a single molecular sensor, and the composite response will 
the fluorescence change is between 35 and 55%. In another be used for characterization and selection. 
embodiment the fluorescence change is between 55 and 75%. Proof of concept of DNA-based array of cross-reactive 
In another embodiment the fluorescence change is between hydrophobic DNA receptors: FIG. 16 shows the use of three 
75 and 125%. In another embodiment the fluorescence fluorescent junctions on a fluorescence plate reader to dem- 
change is between 125 and 500%. In another embodiment the i o  onstrate, how three molecules, cocaine, deoxycholate and 
fluorescence change is between 500 and 1000%. In another corticosterone could be fingerprinted by this small array. A 
embodiment the fluorescence change is greater than 1000%. single molecular sensor will not be able to identify an 
unknown molecule, but an array of three sensors would be 
able not only to identify these molecules, but also to report Design and Methods 
A ‘lass Of hydrophobic receptors based On DNA can be 15 concentration. Importantly, previous research has demon- 
trained to analyze complex mixtures, The limit of sensitivity 
rationah’ varied in ~Jructure and can fold reliably to Yield strated that arrays could be connected to neural networks, and 
of an array that consists of only three Sensors without redun- 
dancy is 2 pM forcorticosterone, 10 pM forcholic acid and 25 
families of receptors. Some receptors can be adapted to yield 
and an Of these 
Provide a fingerprint for hydrophobic to 
identification by olfaction. One can construct families of 2o p~ for cocaine, This sensitivity is sufficient for the direct 
hydrophobic receptors for steroids and the behavior of arrays urinalisys ofthe corticosteroids in urine or bile acids in feces, 
of Sensors based on these receptors can be studied. This But, one can expect to improve sensitivity of arrays to nano- 
approach can be extended to non-hydrophobic molecules, molar by a combination of screening of large number of 
like oligosaccharides. molecular sensors and parallel readouts from multiple redun- 
Site-sPecific, randommutagenesis and footprinting studies 25 dant sensors. The latter was demonstrated earlier as a viable 
led that cocaine binds in a hydrophobic Pocket defined by approach to increase sensitivity. The current sensitivity is 
unstacked base pairs forming a three-way junction with one sufficient for determination of corticosteroids in urine, 
stem of the junction containing mismatched base pairs (Kd -1 overall, studies demonstrated versatility of stoichiomet~c 
PM) AcCordinglY, (through competitive gel equilibrium fil- and catalytic sensors based on nucleic acids. However, there 
tration) a collection of hydrophobic molecules for the capac- 30 is an inadequacy ofthe existing t ec~o log ie s  that use in vitro 
ity to bind to this junction. Identified were various steroids selection and amplification to isolate aptamers as the first step 
and 1aW molecules were screened With hydrophobic Sur- to obtain fluorescent molecular sensors. Namely, the limited 
faces as ligands forthis receptor (estimated Kd’s ranged from structural motifs (i.e. mostly unstacked bases and base-pairs) 
mid-nanomolar for brucine, -1 pM for corticosterone, up to result in the inability to produce significant specificity for 
100 pM for deoxycholic acid). 35 hydrophobic molecules. This lack of specificity is a general 
This discovery was turned into the first colorimetric sensor problem in recognition of hydrophobic molecules by both 
for cocaine in the following manner: It was determined that synthetic and biomolecular receptors, and makes them appli- 
minimal hydrophobic pocket (other than intercalation bind- cable only within certain contexts (e.g. ultra-high throughput 
ing mode) in DNA is defined by two coaxially stacked stems. screening in controlled environment). The similar problem 
A collection of hydrophobic dyes were screened for binding 40 will exist in the analytical methods based on nucleic acids for 
to coaxially stacked stems (including a mismatched junc- determination ofoligosaccharides. While moderate selectiv- 
tion), and identified a group of indocyanine dyes as binders. ity for binding to the targeted disaccharide has been reported, 
Cocaine displaced one dye in particular from the mismatched the structural similarity of these molecules will dictate sig- 
junction and this was used to construct first visual molecular nificant cross-reactivity. 
sensor for cocaine. Similar screening procedure could be used 45 The approach according to the present invention is differ- 
for any other ligand-aptamer couple. (See FIG. 13) ent from the aptamer-based approaches that have been used 
Next, we directly introduced of fluorophore into nucleic earlier. Perhaps the most important novel aspect is the real- 
acid junction. In each junction structure, a single phosphodi- ization that one can take advantage of the lack of specificity 
ester was substituted functionality within junction with a for hydrophobic molecules, if these receptors are organized in 
phosphorothioate group (FIGS. 14 and 15). In the next step 50 arrays or crossreactive sensors. Thus, instead of isolating 
modified junctions containing this uniquely reactive site were specific binders through in vitro selection and amplification 
treated with an excess of thiol-reactive fluorophores (either of oligonucleotide from libraries in the initial stage, one can 
iodoacetamide or bromo acetamide derivatives of fluoro- construct a series of incrementally different fluorescent oli- 
phores, and in the case of bimane fluorophores, monobromo- gonucleotidejunctions, whichcan be screenedforresponse to 
bimane). A series of receptors capable of transducing binding 55 a panel of analytes. 
of hydrophobic molecules into increase (for steroids and Based on the results, the size of these junctions is espe- 
cocaine) of fluorescence intensity was constructed. This cially well suited for characterization of hydrophobic space 
increase resulted from a change in fluorophore microenviron- of steroids, as the steroid core has a molecular volume that 
ment, likely leading to the decrease in fluorophore quenching approximately corresponds to the size of the cavity in the 
by neighboring guanines. Change in fluorescence could be 60 three-way junction. The steroidal hydrophobic space is actu- 
used to quantitate a known analyte that binds junction. How- ally a complex multidimensional space, as polarity of mol- 
ever, the crossreactivity with other hydrophobic molecules ecules will not be the sole determinant of interactions with 
rendered these sensors unlikely candidates for a “lock and individual hydrophobic molecular sensors, but rather a com- 
key” approach to sensors, limiting them to highly controlled bination of hydrophobicity, molecular volume, shape of the 
environments, like in vitro high-throughput screening for 65 molecule, its flexibility and the ability of the molecule to 
cocaine hydrolase activity. Each molecular sensor is a mix- induce conformational changes in various receptors (Le. 
ture of two diastereomers at phosphorous, which are sepa- induced fit). One may expect numerous variations in struc- 
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tures of hydrophobic junctions to give subtle differences in junction substituted with phosphorothioates, except in the C, 
interactions with very similar compounds (e.g. testosterone and D, symmetrical junctions. Three-way junctions with mis- 
vs. epitestosterone-hallmark of anabolic abuse in doping), matches be made with an additional phosphorothioate sub- 
providing one with the opportunity to precisely characterize stitution at the stem containing mismatches. Synthesis can be 
presence and ratios of closely related compounds. This level 5 performed at 250 m o l  scale, which would be expected to 
of discrimination cannot be expected from polymer- or yield approximately 20 nmols of a final product. Also, one 
chemical receptors-based approaches to detect hydrophobic may use previously reported cyclodextrin-based molecular 
molecules, and is a unique characteristic of the biomimetic sensors to expand the coverage of hydrophobic space. 
system. Each phosphorothioate-containing junction may then be 
Nucleic acid junctions are formed at the intersection of i o  coupled to six different fluorescent dyes, which may be used 
three and more double helixes. The first cocaine-binding in their commercially available thiol-reactive forms. 
aptamers were previously isolated and these structures were (Flourescein iodoacetamide, Texas Red bromoacetamide, 
characterized through mutagenesis as three-way junctions EDANS iodoacetamide, Bromobimane, DANSYL iodoac- 
with mismatched stems (3). The fully matched analog of the etamide, BODIPY 5071545 iodoacetamide). Preferably all 
aptamer was found to bind cocaine less efficiently, but was 15 molecular sensors in arrays are based on a single fluorophore. 
able to bind other hydrophobic molecules. The capacity of Standard coupling procedure may be used (molar ratio of a 
various nucleic acid junctions to incorporate hydrophobic dye to oligonucleotide 3: 1, dye dissolved in DMSO, coupling 
molecules was reported during early footprinting studies (4) in TRIS buffer, six hours at room temperature for iodoacetoa- 
and confirmed by the isolation of anti-steroid aptamers com- mides, twelve hours for bromo derivatives). Excess dye may 
prised of fully matched three-way junctions (5). The three 20 be removed on Sephadex G-25 microspin columns, and so 
exposed aromatic surfaces of unstacked base-pairs in three- obtained fluorescent junction may be sufficiently pure to pro- 
way junctions form a lipophilic cavity approximately 11 8, in ceed with screening. Upon modification, each dye becomes 
diameter, which is capable of binding a wide range of hydro- part of the hydrophobic pocket. Thus, this procedure effec- 
phobic guest molecules (4). The framework provided by the tively yields over 1000 sensors with incremental variations in 
stems would ensure proper folding regardless of the modifi- 25 structures. One may be able to construct and purify in this way 
cations at the junctions. The ability to vary easily and system- at least 12 sensors per day. Eachmolecular sensor (12 per day) 
atically the structure of these receptors through the introduc- may be tested in four measurements for reactivity against 
tion of mutations, mismatches and chemical modifications eight compounds at concentrations of 20 pM in buffer: dehy- 
represents an important advantage over other hydrophobic droisoandrosterone 3-sulfate, testosterone 17-sulfate, epites- 
hosts (6), such as cyclodextrines and calixarenes. According 30 tosterone 17-sulfate, corticosterone-21 -sulfate, glycodeoxy- 
to preliminary screening, each junction could interact with cholic acid, amphetamine, naloxane and cocaine. Sensors 
multiple guest molecules, and each guest could interact with may be tested in fluorescence plate readers (12 sensorsx8 
multiple functions. Thus, this system seemed suitable to test analytesx4 redundancies in one 384-well plate) with excita- 
the utility of sensors based on three-way junctions as the basis tion and emission filters of appropriate wavelengths. Sensors 
of arrays capable of generating fingerprints. In this case, the 35 that respond to any of these analytes may be selected for 
fingerprints would be characteristic for hydrophobic surfaces further testing, and fully characterized for response in spec- 
and the resulting array would be a primitive solution-phase trofluorimeter. Final cutoff value for selection of sensors for 
mimic of the olfactory system. the second phase will be reproducible 2% change in fluores- 
Another consideration was a reporting event (7). Aware of cence to 5 pM solution of any of the analytes. The sensitivity 
the seminal work of Ueno and colleagues on cyclodextrines 40 may be further through multiple parallel readouts (through 
(X), the possibility that introduction of a fluorophore into the microprinting onnitrocellulose filters one couldachieveup to 
hydrophobic cavity of the junction would yield a molecular one thousand repeated measurements, leading to the theoreti- 
sensor based on the internal displacement of the fluorophore cal improvement in the signal to noise ratio of 100). 
by a guest molecule was tested. The invention provides syn- One may demonstrate synthesis of molecular sensors on 
thesis of fluorescent-signaling sensors based on three-way 45 surfaces. Junctions showing promise as sensors be custom 
junctions and demonstrates that an array of such sensors is made with 5' amine and 5' biotin and with a single phospho- 
capable of fingerprinting hydrophobic molecules in solution. rothioate substitution. (See FIGS. 18 and 19). The purpose of 
Synthesis and Characterization of Individual Junctions: this derivative is to achieve simple coupling chemistry to 
Individual oligonucleotides may be custom made. A basic set beads and surfaces. Oligonucleotides may be incubated with 
of unmodified oligonucleotides may consist of approxi- 50 Affigel-10 (NHS-activated carboxy agarose), with Streptavi- 
mately 100 junctions. Illustrative examples are given in FIG. dine AgaroseAffinity Gel, withNHS-carboxy plates and with 
17. Variations in the size and shape of hydrophobic pocket of epoxy-derivatized glass slides. Upon the completion of reac- 
junctions will be introduced by variations in: (1) base pairs tion, surfaces may be treated with thiol reactive fluorophores, 
making a junction (e.g., Jl-J4); (2) introduction of mis- and upon extensive washing of excess dyes, these surfaces 
matches withinjunctions (J5), outside of (J6) ofboth (J7); and 55 may be tested for the response to analytes. For testing one 
(3) bulges (J11). Another source of variations is the position may use a fluorescence plates reader, except for glass slides, 
of phorphorothioate group. Upon functionalization, each of which can be tested with fluorescence scanning microscopy 
these isomers will give distinct molecular sensor (as demon- (shared facility at Columbia University Health Sciences 
strated in preliminary results, where a phosphorothioate Campus). Solid-state synthesis opens a possibility to combi- 
group was substituted at all three positions within junctions, 60 natorial approach to synthesis and characterization of junc- 
and different responses were obtained with each ensuing tions. 
sensor to cocaine). Accordingly, each junction may be trans- One can expect to have at least one hundred unique recep- 
formed into three to five different phosphorothioate analogs tors to proceed to the second phase. Specific chemistry has 
(black dots in FIG. 17 represent position of phosphorothio- been already developed and tested on 15 different junctions 
ate). 65 earlier, and it has worked in each case. Some of the junctions 
Specifically, fully matched three-way junctions be indi- could be less reactive toward derivatization reagents; how- 
vidually made with each of the phosphodiester bonds within ever, this problem could be circumvented by the prolonged 
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incubation times, increased amounts of fluorophores and 
changing ionic strength. One may also not be able to use some 
of the fluorophores with some of the unnatural nucleotides, 
because of the potential for strong quenching. Furthermore, 
some fluorophore may have too small a fluorescent response, 
and may end up being unsuitable for solid-state approaches. 
One may initially focus efforts on fluorescein and its analogs, 
fluorescein shows the highest increase in fluorescence upon 
displacement from the hydrophobic cavity. For example, 
some junctions, as shown in FIG. 26, showed an increase in 
fluorescence up to 200%. One may attribute this favorable 
property of fluorescein to the most efficient short-distance 
fluorescent quenching by proximal guanidines. 
Construction and characterization of crossreactive arrays. 
From the sensors selected in the phase 1, one may take 96 and 
integrate them first in 384-well plates and, eventually, in an 
array based on 1586-well plates. Arrays on 384-well plates 
would have four readouts, while arrays on 1586-well plates 
would have 16 readouts for each molecular sensor. While one 
would expect that 384-well plates will be sufficiently sensi- 
tive for initial experiments, 1586-well plates would have sev- 
eral advantages in future applications. First, they would allow 
characterization of each urine or serum sample with 96 
molecular sensors with 16 measurements each, thus increas- 
ing sensitivity through redundant readouts. Also, even for the 
initial experiments, where an increase sensitivity below 1 pM 
of analytes is unneeded, 1586-well plates would lead to the 
significant reduction in the amount of sensor used for each 
fingerprint. In these experiments, which would use smaller 
number of sensors, one could run multiple urine samples on 
one plate. 
Arrays on Solid Surfaces 
In order to better mimic the olfactory system, it is desire- 
able to increase even more number of crossreactive sensors 
per array, and number of parallel reading per sensor. 
For this purpose, one may work to develop microchip and 
microbeads based methods. This also may allow the use of 
each array multiple times, and will help integration of arrays 
with neural networks. 
Initial results indicate that nucleic acid junctions operate 
well in various environments, and that they will be functional 
on nitrocellulose filters, which is a standard approach devel- 
oped for applying macromolecules (proteins, oligonucle- 
otides and oligosaccharides) to microarrays. This would be 
the most direct approach, as it would not need any further 
covalent modifications to attach oligonucleotides to micro- 
chip. One possible drawback is that one could not be certain 
that this attachment mode would work for all molecular sen- 
sors tested in solution, and in some cases the properties of 
sensor may be significantly changed. On the other hand, the 
favorable partition between membrane impregnated with 
hydrophobic receptors and solution may actually increase 
sensitivity. However, alternative approaches exist for attach- 
ing oligonucleotides to microchips, some of which may be 
developed in the sub-goal 4 of the phase one. For example, 
one can attach either amine or thiols to 5' end and attach 
sensors to epoxide slides or gold microchips. The advantage 
of these two methods would be that one could use lower 
concentrations of oligonucleotides in synthetic steps. In all 
three approaches, in order to prevent formation of oligomeric 
sensors or self-quenching, one could control density of sen- 
sors on a spot by diluting sensor with irrelevant oligonucle- 
otide, or unlabeled junctions. Once one selects set of molecu- 
lar sensors that can operate on microchips, they can test both 
intra- and inter-chip reproducibility of hydrophobic finger- 
prints. 
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Fingerprinting of standard steroids, alkaloids and mix- 
tures: One can first obtain fingerprints of various standard 
samples of steroids and alkaloids and their mixtures in buff- 
ers. One can perform the fingerprinting in urine matrix with 
5 standard additions of soluble forms of steroids. Urine matri- 
ces will be generated from specimens from healthy persons 
by removing all steroids by repeated solid phase extraction 
procedures, and then individually characterize representative 
constituents of urine. 
One can first test arrays for reproducibility fingerprints of 
steroids that were used to select individual sensors. Next, this 
test can be expanded to other commercially available steroids. 
Especially important will be characterization of steroids that 
are solubilized in the similar way as in urine and bile, like 
15 testosterone 17-sulfate, corticosterone-21 sulfate, tauro- 
cholic and glycocholic acids, deoxycholic acid and dehydroi- 
soandrosterone 3-sulfate, androstanedioll7-glucuronide and 
androstanone 3-glucuronide. These experiments will also 
help determine the smallest size of an array, which will be 
20 useful in initial demonstrations. Next, one can characterize 
calibrating mixtures that are commercially available (e.g. bile 
acids calibrators from Sigma). Alternatively, one can perform 
all tests in solution of lyophilized urine fraction of MwelO, 
000 (Sigma). Then, one can demonstrate that they can repro- 
25 ducibly detect changes in fingerprints of urine upon addition 
of one component in excess. 
Demonstration of diagnostic applications of hydrophobic 
fingerprints of urine: As the first demonstration of the meth- 
odology, one may validate arrays on 24-h urine samples send 
30 for determination of 17-ketosteroids (17-KS) and 17-hy- 
droxycorticosteroids (17-OHCS) by endocrinologists. In this 
way one would be able to compare whether fingerprints could 
substitute values obtained through standard methods, and 
would be able to correlate fingerprints with specific disease 
35 states. Namely, these two tests (in combination with ACTH) 
can be used for diagnosing and differentiating Cushing syn- 
drome (see Table 1). 
10 
For 
40 
Differentiating 
Cushing Cushing Adrenal Adrenal 
Syndrome Disease Adenoma Cancer 
45 Urinary 170HCS High High High 
High 
Urinary 17KS High Low very 
50 example, a cortisol-producing adrenal adenoma is suggested 
ifthe urinary 17-OHCS is markedly elevated, while 17-KS is 
decreased or minimally changed. Adrenal carcinoma is sug- 
gested if both urinary 17-OHCS and 17-KS are strikingly 
elevated. As carefully timed urine collection is a prerequisite 
55 for all excretory determinations, urinary creatinine level will 
be measured to determine the accuracy and adequacy of the 
collection procedure. 
In the initial experiments one may use the smallest array 
that will provide the clean differentiation between soluble 
60 model compounds tested above. There is a possibility that 
during comprehensive screening one may come up with a 
single sensor which would give immediate readout of a gross 
abnormality in urine which could be correlated to a specific 
disease state. This would be significant accomplishment, as it 
65 would allow eliminated multi step procedures that are cur- 
rently used. Importantly it would not diminish interest in the 
more complex arrays. However, it is most likely that one will 
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have to use array of several sensors to distinguish clearly 
fingerprints ofthese three diseases. One ofthemost important 
immediate applications of arrays will be the screening for 
inborn errors of corticosteroid metabolism. For example, 
congenital adrenal hyperplasia, which occurs in 1 : 15,000 
births, is characterized by overproduction of androgens. A 
complex multicomponent analytical procedure has been pro- 
posed to characterize infants with disorders of adrenal steroid 
production and excretion. With arrays, one would be able to 
achieve simple and rapid detection of exact defect, leading to 
a routine procedure. 
With larger arrays one would also be able to pick up fine 
differences in solubilizing groups and metabolites, which was 
not possible before, without elaborate and impractical proce- 
dures. For example, fractionation of urinary 17-ketosteroids 
is reported to be an effective test in the evaluation of hirsut- 
ism. While plasma and total urinary 17-KS were elevated in 
only 21% of the patients, elevated concentration of indi- 
vudual androsterone, etiocholanolone, and dehydroepi- 
androsterone were elevated in 81% of the samples as deter- 
mined by gas chromatography of hydrolysates. With the 
larger array one should be able to fingerprint this mixture 
without difficulties. 
Sample Analysis 
All samples sent for free cortisol, 17-KS and 17-OHCS 
determination can be handled in following manner: One ali- 
quot (12 mL) may be sent to a service such as LabCorp for 
17-OHCS determination; other aliquot (25 mL) may be sent 
to LabCorp for 17-KS determination, while the third aliquot 
(15 mL) will be used by to obtain fingerprints. 
Fingerprinting be performed by taking 50 pL aliquots of 
sterile filtered urine (for 386-well plate) and adding them to 
each well containing buffered solution of individual molecu- 
lar sensors (5 pL) and by reading the fluorescence at the 
appropriate excitation and emission wavelength after 10 min- 
utes. 
Sensors have been demonstrated to operate well in buff- 
ered bodily fluids and that binding to serum proteins does not 
interfere with fluorescence changes due to presence of 
cocaine. The procedure would be a single step procedure, as 
one would not expect solubilizing groups (mostly sulfates and 
glucuronides) on steroids to influence readout, for as long as 
they are on the same position. Thus, in a single-step mix and 
measure procedure one could obtain a reliable readout of 
steroids in urine. In contrast to standard spectrophotometric 
methods, one would not expect interference from other small 
molecules that have no large hydrophobic surfaces. 
In the initial stage of the process one may compare finger- 
prints obtained directly from urine with those obtained after 
concentration of steroids through solid phase extraction 
(SPE), followed by enzymaticichemical hydrolysis and nor- 
mal phase SPE. While these two methods would give differ- 
ent fingerprints, one can establish equivalency in detecting 
gross abnormalities. 
Results and Discussion 
Construction of three-way junction-based sensor: sensors 
derived from a basic set of five three-way junctions, were 
screened withvarious degrees and positions ofmismatches in 
the S3 stem (FIG. 22). They were: cocaine binding MNS 
4.1-32F33, its fully matched analog fmtch-32F33, and three 
junctions with single base-pair mismatches: A23-32F33, 
A24-32F33 and T25-32F33. All junctions bind various ste- 
roids and cocaine with micromolar dissociation constants. 
This cross-reactivity is to be expected from a receptor with a 
primary recognition mechanism based on hydrophobic inter- 
actions. In addition to junctional mismatches, fluorophore 
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positional isomers of MNS4.1: 4.1-7F8, 4.1-21F22, 4.1- 
22F23,4.1-31F32 and the above-mentioned 4.1-32F33 (FIG. 
23). In total, nine sensors were screened initially. 
Although fluorophores have been introduced stochasti- 
5 cally outside of the binding pocket of an anti-ATP aptamer, by 
the individual substitution of standard bases with fluorescent 
analogs to yield successfully ATP sensor, (9) this method did 
not appear particularly suitable for the introduction of fluo- 
rophores directly into the hydrophobic pocket. Instead, a 
i o  two-step method was adapted for the construction of sensors, 
in which a single phosphorothioate group was introduced in 
an aptamer, followed by the selective functionalization of this 
group with a thiol-reactive fluorophore (10) (FIG. 24). This 
method is especially convenient when rapidly screening vari- 
15 ous fluorophores as signaling components, at various posi- 
tions of oligonucleotide-based sensors. The drawback of this 
method is that the sensors are obtained as mixtures of diaste- 
reomers at phosphorous, which interact differently with 
ligands. Although diastereomers are separable by ligand-af- 
20 finity chromatography, for array work one may use the mix- 
tures directly. Hereafter, each pair of diastereomers will be 
referred to as a single sensor. 
At first, a sensor was devised based on our cocaine-binding 
junction MNS4.1. Accordingly, an oligonucleotide was con- 
25 structed in which a single phosphodiester bond between G32 
and G33 at the rim of the putative three-way junction was 
substituted with a phosphorothioate group. This derivative 
was coupled with a series of thiol-reactive fluorophores (1 1). 
While many fluorophores yielded moderately successful 
30 cocaine sensors, focus was put on a fluorescein-modified 
derivative 4.1-G32FG33, which displayed an unusually 
strong three-fold increase in fluorescence upon binding of 
cocaine, with a dynamic range from 50 pM to 5000 pM. The 
magnitude ofthe increase in fluorescence compares favorably 
35 to all previously reported monofluorophoric aptameric sys- 
tems, including those that were isolated through in vitro 
selection (12). The excellent signaling of this monofluoro- 
phoric aptamer could be rationalized by the possibility that 
several proximal guanosines in the non-canonical stem pro- 
40 vide a potent quenching of fluorescein (13). Although the 
affinity of the aptamer for the cocaine diminished with fluo- 
rescent labeling, the sensor preserved initial selectivity of the 
aptamer for cocaine over less hydrophobic cocaine metabo- 
lites, benzoyl ecgonine and ecgonine methyl ester, making it 
45 a useful tool for the high-throughput screening of cocaine 
esterases (14). 
In order to characterize the affinity of 4.1-G32FG33 for 
hydrophobic ligands, this junction was screened for binding 
to three steroids, deoxycorticosterone 21 -glucoside (2), dehy- 
50 droisoandrosterone 3-sulfate (3) and deoxycholic acid (4). 
These steroids are potential targets for “mix and measure” 
assays ofurine samples. The first two steroids are conjugated 
members of the 17-ketosteroid (17-KS) and corticosteroid 
(including 17-hydroxycorticosteroid or 17-OHCS) groups. 
55 They have very similar hydrophobic shapes in solution and 
differ mostly in the position of the solubilizing groups. These 
steroids are of interest clinically because a change in their 
ratio indicates a gross abnormality in steroidogenesis and 
differentiates various forms of Cushing’s disease. Current 
60 assays are cumbersome, multi-step procedures. The third ste- 
roid is a representative bile acid, which is determined in 
clinical samples to diagnose abnormalities in liver function. 
The reference values for 17-KS, 17-OHCS and bile acids in 
urine and bile are well within the sensitivity ranges of our 
65 sensors (15). FIG. 22 shows the sensor response to the 
cocaine and the three steroids. The 4.1-32GsFG33 clearly 
demonstrates the ability to react differentially with various 
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hydrophobic molecules. Yet, low specificity of responses each junction differed, indicating that the maximal absolute 
would typically invalidate such a sensor. Accordingly, eight fluorescence value may be dependent on the interactions of 
additional sensors were constructed and, as above, and estab- fluorophores with the side chains as well. On the other hand, 
lished that seven of them (all but 4.1-21F22) responded with all sensors structurally closer to the fmtch junction bound 
satisfactory intensity to hydrophobic molecules. 5 strongly to all steroids, including deoxycholic acid, while 
Fingerprints of ligands: For each ligand solution screened, they bound poorly to cocaine. The strong sensing ofthe cholic 
the screening results were organized into a fingerprint for that acids by the fully matchedjunction could be rationalized with 
ligand (FIGS. 27 and 28). The power and advantage of this the slightly larger and more symmetric shape of the fully 
approach in comparison to the classic sensor approach is matched junction compared to the mismatched junction and 
clearly demonstrated by the following example: Concentra- i o  with the less planar structure of cholic acids. The weak inter- 
tions were taken of the four ligands that provided a response 
of similar intensity (50-70%) to the sensor 4.1-32F33 (eighth 
bar in FIG. 27): 1-500 pM, 2-32 pM, 3-125 pM, and 4-2 mM. 
Presented with these four samples, a single sensor would not 
be able to disstinguish them. On the other hand, the array 15 
clearly and reproducibly distinguished the solutions of the 
three steroids from each other and from cocaine (FIG. 29). 
FIG. 28 provides the minimal characteristic fingerprints for 
all tested concentrations of the four ligands. Several com- 
ments are in order at this noint: Firstlv. onlv four sensors were 20 
actions of cocaine with the fully-matched junction are con- 
sistent with exclusive isolation of a mismatched junction 
through in vitro selection and amplification on a cocaine 
affinity column (5). The lack of strong signaling of cholic acid 
by the mismatched junctions is consistent with the reported 
isolation of a fully matched junction during in vitro selection 
and amplification using a cholic acid affinity column (4). That 
other steroids seem to bind very well to both structures may 
suggest their different orientations within the two junctions. 
Of narticular mechanistic interest is the observation that 
,l i 
needed to distinguish these four compounds unambiguously. samples of corticosterone 2 and androsterone 3 used for dem- 
The remaining four sensors, although functioning well, were onstration in the FIG. 27 show a proportional response to all 
redundant for this task. Secondly, with multiple batches of fivejunctions containing anA23-G31 mismatch base pair, but 
individual sensors, each concentration of each ligand had a show very different responses to junctions containing a C23- 
unique fingerprint (shape-defined as a ratio of intensities)- 25 G31 matched pair. This may be indicative of the position of 
andor intensity. Shapes of fingerprints are not conserved over 
wide concentration ranges. Importantly, the conservation of 
fingerprint shape is not a requirement for array-based 
approaches, where individual arrays are usually incorporated 
with neural networks and trained to recognize exemplary 
solutions of interest. Thirdly, molecules widely different in 
hydrophobic properties are easily recognized with small sub- 
sets of sensors in arrays. Specifically, any solution of cocaine 
can be easily distinguished from any solution of deoxycholic 
acid or anv solution containing two urinarv metabolites based 
these two steroids in the junctions, whereas it is possible that 
the junction with proximal mismatch accommodates the cen- 
tral region of the steroids without any interactions with solu- 
bilizing polar groups. 
Of note are the types of structural variations near the junc- 
tion, available: First, the positions of mismatches have the 
most striking influence on the interactions with hydrophobic 
molecules. The gross shape of the junction is apparently 
defined through mismatches (and bulges, not used here). Sec- 
35 ond. the nositional isomers of sensors have different shanes 
30 
u I I  
on the characteristic ratio of responses by, for example, 4.1- and charge distributions within the hydrophobic pockets. For 
32F33 and fmtch-32F33. However, corticosterone and example, 4.1-32F33 and 4.1-22F23 have clearly different 
androsterone derivatives 2 and 3 with very similar hydropho- relative response to cocaine than with deoxycholic acid, with 
bic shapes are more challenging to distinguish; up to four more negatively charged junction (4.1-22F23) binding 
sensors were needed to remove the ambiguity at all tested 40 cocaine more strongly (FIG. 27). Additional sources of varia- 
concentrations. tions are the choice of of fluorophore, the use of modified and 
Another experiment tested the ability of these sensors to unnatural oligonucleotides, the substitution of phosphodi- 
obtain useful fingerprints in complex mixtures. A sample of ester bonds with analogs, and expansion of the framework to 
urine (Sigma, lyophilized humanmale urine metabolites) was a four-way junction. These additional sources of variations 
compared to aliquots of the same urine spiked with 200 pM 45 could prove important in the pending full characterization of 
concentrations of 2 or 3. The three solutions were differenti- steroid space. Some points have wide standard deviations, but 
ated unambiguously based on their fingerprints obtained this issue is resolved in larger arrays based on optical fibers or 
through the subset of four sensors (FIG. 29). Most of the other beads with individual sensorredundancies. This appears to be 
sensors were unresponsive under these conditions; possibly the strategy usedinthe mammalianolfactory system, wherein 
as a result of saturation by steroids present in urine. Impor- 50 the thousand receptors are expressed in up to one hundred 
tantly, this also demonstrated that a sensor whichmight have million cells. Such redundancies also have the potential to 
been initially considered redundant (i.e. one of the two sen- increase sensitivity and make these large arrays useful in 
sors with identical response to one ligand) can play a key role serum analysis. Finally, there is a small inter-batchvariability 
in the analysis of complex mixtures (cf. fmtch-A23-32F33 within an individual sensor, consistent with moderate varia- 
and fmtch-T25-32F33). Clinical urine samples contain large 55 tions in the diastereomeric ratios, leading to the necessity to 
quantities of various steroidal metabolites and these results train individually each array when more challenging analyti- 
provide a proof-of-concept for fingeprinting gross deviations cal applications are desired. It is an intriguing possibility that 
from clinical norms. these hydrophobic fingerprints are intrinsic characteristics of 
Without extensive structural studies of the individual sen- the hydrophobic region of the molecule, similar to IR patterns 
sors it is not possible to rationalize or generalize the behavior 60 or NMR spectra. In an effort to standardize them, one may 
of the substituted junctions, but some broad comments are pursue the preparative scale synthesis of sensors with large- 
appropriate. For example, assuming 1 : 1 host-guest binding in scale affinity separation of diastereomers. 
all cases, most of the sensors derived from the original 4.1 This invention provides a composition comprising con- 
junction showed the strongest signaling with deoxycorticos- secutive nucleotides the sequence ofwhich is set forth in any 
terone 2, followed by dehydroisoandrosterone 3 and cocaine 65 one of SEQ ID NOS: 154-220, wherein the composition com- 
1 and the weakest interactions with deoxycholic acid 4. How- prises a fluorescent dye and wherein the composition under- 
ever, the maximum fluorescence intensity for each ligand and goes a conformational change upon contact with an analyte 
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and thc fluorcscent dye undergoes a change of fluorescence 
upon the conformational change. 
This invention further provides the instant composition, 
wherein the fluorescent dye is chosen from the group consist- 
ing of fluorescein, Oregon Green, JOE, HEX, TE,T Alexa 5 
Fluor, Rhodamine Green, eosin, erythroscein, and BODIPY 
related dye, wherein the fluorescent dye is a fluorescein 
derivative, andwhereinthe fluoresceinderivative comprises a 
substituent attached to an aromatic carbon of a fluorescein. 
This invention further provides the instant composition, 10 
cocaine, cortisone, sodium deoxycholate, dehydroisoandros- 
terone 3-sulfate, or deoxycorticosterone 21 -glucoside. 
diluted with buffer containing sensors (5 pL of sensor solu- 
tion in 75 pL of binding buffer) followed by reading on the 
plate reader. 
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Materials and Methods 15 
Materials: All oligonucleotides were custom made and 
HPLC purified by Integrated DNA Technologies Iilc. (Cor- 
and used as received. Liophilized human male urine metabo- 
lites and steroids were purchased from Sigma. Cocaine was 20 
obtained through the National Institute of Drug Abuse. 
Instrumental: Initial characterization of fluorescent spectra 
for MNS4'1-32F33 and fmtch-32F33 were performed On 
Hitachi Instruments Inc. ( S a  Jose, Calif.) F-2000 Fluores- 
alville, I ~ ~ ~ )  or ~ r i i k  B otechnologies (sari ~ i ~ ~ o ,  Calif,) 4) LU, M.; GuO, Q.; Mueller, J. E.; KemPer, '.; Studier, F.W.; 
Spectrophotometer with Hamamatsu Xenon 25 Sot, 2000, 122, 7835-7836; b) Castellano, R, K,; Craig, S, 
L,; Nuckolls, C,; Rebek, J, Jr, J,h, Chem, Sot, 2000, 122, 
7876-7882; d) reference 3a. c) Breslow, R,, Dong, D, S,; 
Experiments were performed at the excitation 
480 nm and emission Scan at 500-600 nm. 
Of 
assays were 
performed using a Wallac Victor2 1420 Multilabel Counter 
(PerkinElmer Instruments, Shelton, Corn.) in 96-well plates 7) De Silva, A, p,; Gunaratne, H, Q ,  N,; Gunnlaugsson, T,; 
E. Chem. Rev. 1997, 97 (15), 1515-1566 and references ters (Aem=530+/-10 nm, hexc=480+/-10 nm). 
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6 mM KCI), 40 pL of deionized water and 5 pL of6-~Odoac- mura, A,; Ikeda, T.; Toda, F.; Ueno, A. J. Am. Chem. SOC. 
etamido fluorescein (Molecular Probes, Eugene, Oreg.) in 35 1996, 118, 10980-10988 and references therein. 
( l  mg'lo pL) were incubated at room temperature 9) The aptamer-based molecular sensors for ATP with fluo- 
(for mismatched junctions) or at 50" C. (fully matched junc- rophore in the proximity, but outside of the binding site, 
tions). After 90 minutes for heated and 180 minutes for room were reported by: haveri, S, D, et J, ~ m ,  Chem, sot, 
temperature mixtures, reactions were applied to Sephadex 2000, 122, 2469, 
G-25 column (I .8 mL) and fluorescent macromolecular frac- 40 10) Fidama, J, A,; ozaki, H,; ~ ~ L ~ ~ ~ h l i ~ ,  L, w, J, ~ m ,  
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sors were diluted in binding buffer with 2 mM MgCl, to techol, 2000, 18(12) 1293-1297. 
achieve response between300 and 1000 fluorescenceunits on 13) The distance-dependent quenching influence of p a -  
the plate reader. Then, standard dilutions of ligand concen- nosine residues has been used as a tool to probe conforma- 
trations were made in the solution of sensors on 96-well 50 tioninDNAmolecules: &emeyer, J.-P.; Mame, N.; Sauer, 
plates. All measurements were performed in triplicates. M. Anal. Chem. 2000, 72, 3717-3724 and references 
solved in 35 mL of water and pH adjusted to 7.4 by addition 
of 300 uL of 10N NaOH and 1 mL 1M TRIS buffer (PH 7.4). 55 
Urine was spiked with deoxycorticosterone 21 -glucoside 2 
and dehydroisoandresterone 3-sulfate 3 to 200 pM concen- 
tration. Samples of urine or spiked urines (25 pL) were 
Chem, Rev, 1998, 98, 1997-201 1, 
(F96 Nunc-immunoplates), using appropriate fil- 30 Huxley, A, J, M,; McCoy, C, p,; Rademacher J, T,; Rice, T, 
45 
Characterization of urine: Urine metabolites were dis- therein. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 200 
<210> SEQ ID NO 1 
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-continued 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 1 
gacaag 
<210> SEQ ID NO 2 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 2 
c t tcaa tgaa gtgggtc 
<210> SEQ ID NO 3 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 3 
gacaag 
<210> SEQ ID NO 4 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 4 
cttcaacgaa gtgggtc 
<210> SEQ ID NO 5 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 5 
gacaag 
<210> SEQ ID NO 6 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 6 
cttccacgaa gtgggtc 
<210> SEQ ID NO 7 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 7 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
6 
17 
6 
17 
6 
17 
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-continued 
gacaag 6 
<210> SEQ ID NO 8 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 8 
cttccacgaa gtggggc 
<210> SEQ ID NO 9 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 9 
gacaag 
<210> SEQ ID NO 10 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 10 
cgtccacgaa gtgggtc 
<210> SEQ ID NO 11 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 11 
gacaag 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 12 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 12 
c t tcaa tgaa gtgggtc 
<210> SEQ ID NO 13 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 13 
gacaag 
17 
6 
17 
6 
17 
6 
<210> SEQ ID NO 14 
<211> LENGTH: 17 
<212> TYPE: DNA 
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<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 14 
cttcaacgaa gtgggtc 
<210> SEQ ID NO 15 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 15 
gacaag 
<210> SEQ ID NO 16 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 16 
cttccacgaa gtgggtc 
<210> SEQ ID NO 17 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 17 
gacaag 
<210> SEQ ID NO 18 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 18 
cttccacgaa gtggggc 
<210> SEQ ID NO 19 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 19 
gacaag 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 20 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 20 
cgtccacgaa gtgggtc 
17 
6 
17 
6 
17 
6 
17 
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<210> SEQ ID NO 21 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 2 1  
gacaag 
<210> SEQ ID NO 22 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 22 
c t tcaa tgaa gtgggtc 
<210> SEQ ID NO 23 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 23 
gacaag 
<210> SEQ ID NO 24 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 24 
cttcaacgaa gtgggtc 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 25 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 25 
gacaag 
<210> SEQ ID NO 26 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 26 
cttccacgaa gtgggtc 
6 
17 
6 
17 
6 
17 
<210> SEQ ID NO 27 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
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<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 27 
gacaag 
<210> SEQ ID NO 28 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 28 
cttccacgaa gtggggc 
<210> SEQ ID NO 29 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 29 
gacaag 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 30 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 30 
cgtccacgaa gtgggtc 
<210> SEQ ID NO 31 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 31 
gacaag 
<210> SEQ ID NO 32 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 32 
c t tcaa tgaa gtgggtc 
<210> SEQ ID NO 33 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
6 
17 
6 
17 
6 
17 
<400> SEQUENCE: 33 
gacaag 6 
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<210> SEQ ID NO 34 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 34 
cttcaacgaa gtgggtc 
<210> SEQ ID NO 35 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 35 
gacaag 
<210> SEQ ID NO 36 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 36 
cttccacgaa gtgggtc 
<210> SEQ ID NO 37 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 37 
gacaag 
<210> SEQ ID NO 38 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 38 
cttccacgaa gtggggc 
<210> SEQ ID NO 39 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 39 
gacaag 
<210> SEQ ID NO 40 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
17 
6 
17 
6 
17 
6 
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<400> SEQUENCE: 40 
cgtccacgaa gtgggtc 17 
<210> SEQ ID NO 41 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 41 
gacaag 
<210> SEQ ID NO 42 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 42 
c t tcaa tgaa gtgggtc 
<210> SEQ ID NO 43 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 43 
gacaag 
<210> SEQ ID NO 44 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 44 
cttcaacgaa gtgggtc 
<210> SEQ ID NO 45 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 45 
gacaag 
<210> SEQ ID NO 46 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 46 
cttccacgaa gtgggtc 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
6 
17 
6 
17 
6 
17 
<210> SEQ ID NO 47 
<211> LENGTH: 6 
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<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 47 
gacaag 
<210> SEQ ID NO 48 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 48 
cttccacgaa gtggggc 
<210> SEQ ID NO 49 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 49 
gacaag 
<210> SEQ ID NO 50 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 50 
cgtccacgaa gtgggtc 
<210> SEQ ID NO 51 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 51 
gacaag 
<210> SEQ ID NO 52 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 52 
c t tcaa tgaa gtgggtc 
<210> SEQ ID NO 53 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 53 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
6 
17 
6 
17 
6 
17 
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gacaag 
<210> SEQ ID NO 54 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 54 
cttcaacgaa gtgggtc 
<210> SEQ ID NO 55 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 55 
gacaag 
<210> SEQ ID NO 56 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 56 
cttccacgaa gtgggtc 
<210> SEQ ID NO 57 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 57 
gacaag 
<210> SEQ ID NO 58 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 58 
cttccacgaa gtggggc 
<210> SEQ ID NO 59 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 59 
gacaag 
6 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
17 
6 
17 
6 
17 
6 
<210> SEQ ID NO 60 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
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<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 60 
cgtccacgaa gtgggtc 
<210> SEQ ID NO 61 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 61 
gacaag 
<210> SEQ ID NO 62 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 62 
c t tcaa tgaa gtgggtc 
<210> SEQ ID NO 63 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 63 
gacaag 
<210> SEQ ID NO 64 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 64 
cttcaacgaa gtgggtc 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 65 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 65 
gacaag 
<210> SEQ ID NO 66 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 66 
cttccacgaa gtgggtc 
17 
6 
17 
6 
17 
6 
17 
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<210> SEQ ID NO 67 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 67 
gacaag 
<210> SEQ ID NO 68 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 68 
cttccacgaa gtgggtc 
<210> SEQ ID NO 69 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 69 
gacaag 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 70 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 70 
cgtccacgaa gtgggtc 
<210> SEQ ID NO 71 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 71 
gacaag 
<210> SEQ ID NO 72 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 72 
c t tcaa tgaa gtgggtc 
6 
17 
6 
17 
6 
17 
<210> SEQ ID NO 73 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
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<400> SEQUENCE: 73 
gacaag 6 
<210> SEQ ID NO 74 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 74 
cttcaacgaa gtgggtc 
<210> SEQ ID NO 75 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 75 
gacaag 
<210> SEQ ID NO 76 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 76 
cttccacgaa gtgggtc 
<210> SEQ ID NO 77 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 77 
gacaag 
<210> SEQ ID NO 78 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 78 
cttccacgaa gtggggc 
<210> SEQ ID NO 79 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
17 
6 
17 
6 
17 
<400> SEQUENCE: 79 
cacaag 6 
<210> SEQ ID NO 80 
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<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 80 
cgtccacgaa gtgggtc 
<210> SEQ ID NO 81 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 81 
gacaag 
<210> SEQ ID NO 82 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 82 
c t tcaa tgaa gtgggtc 
<210> SEQ ID NO 83 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 83 
gacaag 
<210> SEQ ID NO 84 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 84 
cttcaacgaa gtgggtc 
<210> SEQ ID NO 85 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 85 
gacaag 
<210> SEQ ID NO 86 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 86 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
17 
6 
17 
6 
17 
6 
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cttccacgaa gtgggtc 1 7  
<210> SEQ ID NO 87 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 87 
gacaag 
<210> SEQ ID NO 88 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 88 
cttccacgaa gtggggc 
<210> SEQ ID NO 89 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 89 
gacaag 
<210> SEQ ID NO 90 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 90 
cgtccacgaa gtgggtc 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 91 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 91 
gacaag 
<210> SEQ ID NO 92 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 92 
c t tcaa tgaa gtgggtc 
6 
17 
6 
17 
6 
17 
<210> SEQ ID NO 93 
<211> LENGTH: 6 
<212> TYPE: DNA 
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<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 93 
gacaag 
<210> SEQ ID NO 94 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 94 
cttcaacgaa gtgggtc 
<210> SEQ ID NO 95 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 95 
gacaag 
<210> SEQ ID NO 96 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 96 
cttccacgaa gtgggtc 
<210> SEQ ID NO 97 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 97 
gacaag 
<210> SEQ ID NO 98 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 98 
cttccacgaa gtggggc 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 99 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 99 
gacaag 
6 
17 
6 
17 
6 
17 
6 
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<210> SEQ ID NO 100 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 100 
cgtccacgaa gtgggtc 
<210> SEQ ID NO 101 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 101 
ctgggtgaag t a a c t t c  
<210> SEQ ID NO 102 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 102 
gaacag 
<210> SEQ ID NO 103 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 103 
ctgggtgaag caac t tc  
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 104 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 104 
ctgggtgaag cacc t tc  
<210> SEQ ID NO 105 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 105 
cggggtgaag cacc t tc  
17 
17 
6 
17 
17 
17 
<210> SEQ ID NO 106 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
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<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 106 
ctgggtgaag cacctgc 
<210> SEQ ID NO 107 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 107 
ctgggtgaag t a a c t t c  
<210> SEQ ID NO 108 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 108 
ctgggtgaag caac t tc  
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 109 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 109 
ctgggtgaag cacc t tc  
<210> SEQ ID NO 110 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 110 
cggggtgaag cacc t tc  
<210> SEQ ID NO 111 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 113 
ctgggtgaag cacctgc 
<210> SEQ ID NO 112 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
17 
17 
17 
17 
17 
17 
<400> SEQUENCE: 112 
ctgggtgaag t a a c t t c  17 
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<210> SEQ ID NO 113 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 113 
ctgggtgaag caac t tc  
<210> SEQ ID NO 114 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 114 
ctgggtgaag cacc t tc  
<210> SEQ ID NO 115 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 115 
cggggtgaag cacc t tc  
<210> SEQ ID NO 116 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 116 
ctgggtgaag cacctgc 
<210> SEQ ID NO 117 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 117 
ctgggtgaag t a a c t t c  
<210> SEQ ID NO 118 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 118 
ctgggtgaag caac t tc  
<210> SEQ ID NO 119 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
17 
17 
17 
17 
17 
17 
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<400> SEQUENCE: 119 
ctgggtgaag cacc t tc  1 7  
<210> SEQ ID NO 120 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 120 
cggggtgaag cacc t tc  
<210> SEQ ID NO 121 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 123 
ctgggtgaag cacctgc 
<210> SEQ ID NO 122 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 122 
ctgggtgaag t a a c t t c  
<210> SEQ ID NO 123 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 123 
ctgggtgaag caac t tc  
<210> SEQ ID NO 124 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 124 
ctgggtgaag cacc t tc  
<210> SEQ ID NO 125 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 125 
cggggtgaag cacc t tc  
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
17 
17 
17 
17 
17 
17 
<210> SEQ ID NO 126 
<211> LENGTH: 17 
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<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 126 
ctgggtgaag cacctgc 
<210> SEQ ID NO 127 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 127 
ctgggtgaag t a a c t t c  
<210> SEQ ID NO 128 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 128 
ctgggtgaag caac t tc  
<210> SEQ ID NO 129 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 129 
ctgggtgaag cacc t tc  
<210> SEQ ID NO 130 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 130 
cggggtgaag cacc t tc  
<210> SEQ ID NO 131 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 131 
ctgggtgaag cacctgc 
<210> SEQ ID NO 132 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 132 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
17 
17 
17 
17 
17 
17 
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ctgggtgaag t a a c t t c  
<210> SEQ ID NO 133 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 133 
ctgggtgaag caac t tc  
<210> SEQ ID NO 134 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 134 
ctgggtgaag cacc t tc  
<210> SEQ ID NO 135 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 135 
cggggtgaag cacc t tc  
<210> SEQ ID NO 136 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 136 
ctgggtgaag cacctgc 
<210> SEQ ID NO 137 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 137 
ctgggtgaag t a a c t t c  
<210> SEQ ID NO 138 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 138 
ctgggtgaag caac t tc  
17 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
17 
17 
17 
17 
17 
17 
<210> SEQ ID NO 139 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
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<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 139 
ctgggtgaag cacc t tc  
<210> SEQ ID NO 140 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 140 
cggggtgaag cacc t tc  
<210> SEQ ID NO 141 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 141 
ctgggtgaag cacctgc 
<210> SEQ ID NO 142 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 142 
ctgggtgaag t a a c t t c  
<210> SEQ ID NO 143 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 143 
ctgggtgaag caac t tc  
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 144 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 144 
ctgggtgaag cacc t tc  
<210> SEQ ID NO 145 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 145 
cggggtgaag cacc t tc  
17 
17 
17 
17 
17 
17 
17 
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<210> SEQ ID NO 146 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 146 
ctgggtgaag cacctgc 
<210> SEQ ID NO 147 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 147 
ctgggtgaag t a a c t t c  
<210> SEQ ID NO 148 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 148 
ctgggtgaag caac t tc  
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 149 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 149 
ctgggtgaag cacc t tc  
<210> SEQ ID NO 150 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 150 
cggggtgaag cacc t tc  
<210> SEQ ID NO 151 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 151 
ctgggtgaag cacctgc 
17 
17 
17 
17 
17 
17 
<210> SEQ ID NO 152 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
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<400> SEQUENCE: 152 
ataaat 6 
<210> SEQ ID NO 153 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 153 
taaata 
<210> SEQ ID NO 154 
<211> LENGTH: 16 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 154 
gggagacaag gaggtt  
<210> SEQ ID NO 155 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 155 
aacc tcc t tc  aatgaagtgg gtcgaca 
<210> SEQ ID NO 156 
<211> LENGTH: 21 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 156 
t a a t a t a t g a  gggggtccat a 
<210> SEQ ID NO 157 
<211> LENGTH: 20 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 157 
tatggaagga ggcgatat ta 
<210> SEQ ID NO 158 
<211> LENGTH: 30 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
6 
16 
27 
21 
2 0  
<400> SEQUENCE: 158 
gacttggata aatccaacaa tgaagtggtc 30 
<210> SEQ ID NO 159 
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<211> LENGTH: 39 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 159 
gggagacttg gataaatcca acaatgaagt gggtcgaca 
<210> SEQ ID NO 160 
<211> LENGTH: 39 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 160 
gggagacttg gataaatcca acaatgaagt gggtcgaca 
<210> SEQ ID NO 161 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 161 
gacaag 
<210> SEQ ID NO 162 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 162 
cttcaa 
<210> SEQ ID NO 163 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 163 
t999tc 
<210> SEQ ID NO 164 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 164 
CttCCC 
<210> SEQ ID NO 165 
<211> LENGTH: 7 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 165 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
39 
39 
6 
6 
6 
6 
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gactaag 
<210> SEQ ID NO 166 
<211> LENGTH: 7 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: CTTTCCC 
<400> SEQUENCE: 166 
C t t t C C C  
<210> SEQ ID NO 167 
<211> LENGTH: 7 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 167 
t g g t g t c  
<210> SEQ ID NO 168 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 168 
accgta 
<210> SEQ ID NO 169 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 169 
tacgaa 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 170 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 170 
t t c g g t  
<210> SEQ ID NO 171 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 171 
accata 
7 
7 
7 
6 
6 
6 
6 
<210> SEQ ID NO 172 
<211> LENGTH: 6 
<212> TYPE: DNA 
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<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 172 
tatcaa 
<210> SEQ ID NO 173 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 173 
acaata 
<210> SEQ ID NO 174 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 174 
tatcca 
<210> SEQ ID NO 175 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 175 
tggtgt 
<210> SEQ ID NO 176 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 176 
tataca 
<210> SEQ ID NO 177 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 177 
tgttgt 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 178 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 178 
acagta 
6 
6 
6 
6 
6 
6 
6 
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<210> SEQ ID NO 179 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 179 
tacgaa 
<210> SEQ ID NO 180 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 180 
t t c g g t  
<210> SEQ ID NO 181 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 183 
accata 
<210> SEQ ID NO 182 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 182 
ta tcaa 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 183 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 183 
tggggt 
<210> SEQ ID NO 184 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 184 
acaata 
6 
6 
6 
6 
6 
6 
<210> SEQ ID NO 185 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
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<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 185 
tataaa 
<210> SEQ ID NO 186 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 186 
t g t g g t  
<210> SEQ ID NO 187 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 187 
a c c t t a  
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
<210> SEQ ID NO 188 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 188 
taacc t  
<210> SEQ ID NO 189 
<211> LENGTH: 7 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 189 
aagtggt 
<210> SEQ ID NO 190 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
<400> SEQUENCE: 190 
a c c c t t  
<210> SEQ ID NO 191 
<211> LENGTH: 6 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER 
NO BIOLOGICAL SOURCE 
NO BIOLOGICAL SOURCE 
6 
6 
6 
6 
7 
6 
<400> SEQUENCE: 191 
aagcct 6 
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<210> SEQ ID NO 192 
<211> LENGTH: 8 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 192 
aggatggt 
<210> SEQ ID NO 193 
<211> LENGTH: 39 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 193 
gggagacaag gataaatcct  tccacgaagt gggtcgaca 
<210> SEQ ID NO 194 
<211> LENGTH: 4 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 194 
acaa 
<210> SEQ ID NO 195 
<211> LENGTH: 15 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 195 
ttcaacgaag tgggt  
<210> SEQ ID NO 196 
<211> LENGTH: 15 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 196 
ttccgcgaag 9999t 
<210> SEQ ID NO 197 
<211> LENGTH: 15 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
<400> SEQUENCE: 197 
t t cca tgaag tgggt  
<210> SEQ ID NO 198 
<211> LENGTH: 15 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223> OTHER INFORMATION: ARTIFICIAL 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
APTAMER - NO BIOLOGICAL SOURCE 
8 
39 
4 
15 
15 
15 
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<400> SEQUENCE: 198 
t tcaatgaag tgggt  1 5  
<210> SEQ ID NO 199 
<211> LENGTH: 5 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 199 
t t c a a  5 
<210> SEQ ID NO 200 
<211> LENGTH: 5 
<212> TYPE: DNA 
<213> ORGANISM: ARTIFICIAL SEQUENCE 
<220>  FEATURE: 
<223>  OTHER INFORMATION: ARTIFICIAL APTAMER - NO BIOLOGICAL SOURCE 
<400> SEQUENCE: 200 
tggg t  5 
What is claimed: fluorescence auantitated in sten (b) indicates that the 
1. A method of detecting an analyte in a solution compris- 
(a) providing a composition comprising an oligonucleotide 
and a fluorescent moiety attached to the oligonucleotide, 
wherein the oligonucleotide undergoes a conforma- 
tional change upon contact with the analyte, and the 
fluorescent moiety undergoes a change of fluorescence 
upon the conformational change, and wherein the oligo- 
nucleotide comprises a first series of consecutive nucle- 
otides comprising the sequence set forth in SEQ ID 
ing: 
I \ ,  
analyte is present in the solution. 
3o 2. The method of claim 1, wherein two or more composi- 
tions are present. 
3. The method of claim 1, wherein the oligonucleotide 
comprises a phosphorothioate group and a fluorescence moi- 
ety attached to the sulfur of the phosphorothioate group. 
4. The method of claim 1, wherein the solution is a sample 
of a bodily fluid obtained from a subject. 
5. The method of claim 4, wherein the bodily fluid is blood, 
a blood product, urine, a urine product, saliva, a saliva prod- 
35 
NO:1 and a second series of consecutive nucleotides 
comprising the sequence set forth in SEQ ID NO:2, 4o 
wherein the first series of consecutive nucleotides is 
located at the 5' end of the oligonucleotide and the sec- 
ond series of consecutive nucleotides is located at the 3' 
end of the oligonucleotide, wherein a 3' portion of the 
first series of consecutive nucleotides hybridizes with a 45 
uct, or sweat. 
6. Themethodofclaim4, whereinthe subject is amammal. 
7. The method of claim 6, wherein the subject is human. 
8. The method of claim 1, wherein the oligonucleotide 
comprises the following structure: 
5' portion of the second series of consecutive nucle- 
consecutive nucleotides hybridizes with a 3' portion of 
nucleotides in length; I 
of the composition in the absence of the analyte; 
3' 
otides, and wherein a 5' portion of the first series of '\G- - -C' 
I I  
1 :  A 
A - - - T  
C---G\G-G-T-G/ 
the second series of consecutive nucleotides of SEQ ID 
NO:2, and wherein the oligonucleotide is 25 to 120 5o 
'A. 
A. ,+A-.~-T, G 
/ "T (b) quantitating the fluorescence of the fluorescent moiety 
'4. / 
(c) subsequently contacting the composition with the solu- / "T .- G.. / 
tion containing the analyte; 55 :' 'C 
(d) quantitating the fluorescence of the fluorescent moiety 
of the composition in contact with the solution contain- 
ing the analyte; and 
. ,  
* - _ _ - e  
(e) comparing the fluorescence quantitated in step (b) with 
that quantitated in step (d), wherein a change in the 
fluorescence quantitated in step (d) as comparedwith the * * * * *  
